universitat de barcelonadiposit.ub.edu/dspace/bitstream/2445/36153/8/07.hep_bibliografi… ·...

Mecanismes de resposta a la inducció per hipòxia Bibliografia

127

7. BIBLIOGRAFIA 1. Boyle, P. and Ferlay, J. (2005). Cancer incidence and mortality in Europe, 2004. Ann Oncol 16,

481-488.

2. Cahill, D. P., Kinzler, K. W., Vogelstein, B., and Lengauer, C. (1999). Genetic instability and

darwinian selection in tumours. Trends Cell Biol 9, M57-M60.

3. Hanahan, D. and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70.

4. Skobe, M. and Fusenig, N. E. (1998). Tumorigenic conversion of immortal human keratinocytes

through stromal cell activation. Proc Natl Acad Sci U S A 95, 1050-1055.

5. Soussi, T. and Lozano, G. (2005). p53 mutation heterogeneity in cancer. Biochem Biophys.Res

Commun. 331, 834-842.

6. Kirkin, V., Joos, S., and Zornig, M. (2004). The role of Bcl-2 family members in tumorigenesis.

Biochim.Biophys.Acta 1644, 229-249.

7. Fresno Vara, J. A., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., and Gonzalez-Baron, M.

(2004). PI3K/Akt signalling pathway and cancer. Cancer Treat.Rev 30, 193-204.

8. Shay, J. W. and Bacchetti, S. (1997). A survey of telomerase activity in human cancer. Eur J

Cancer 33, 787-791.

9. Perez-Atayde, A. R., Sallan, S. E., Tedrow, U., Connors, S., Allred, E., and Folkman, J. (1997).

Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.

Am J Pathol 150, 815-821.

10. Folkman, J. (1992). The role of angiogenesis in tumor growth. Semin Cancer Biol 3, 65-71.

11. Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer

Inst 82, 4-6.

12. Rofstad, E. K. and Danielsen, T. (1999). Hypoxia-induced metastasis of human melanoma cells:

involvement of vascular endothelial growth factor-mediated angiogenesis. Br.J.Cancer 80, 1697-

1707.

13. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. (1995). Vascular permeability

factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J

Pathol 146, 1029-1039.

14. Fox, S. B. (1997). Tumour angiogenesis and prognosis. Histopathology 30, 294-301.

15. D'Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. (1994). Thalidomide is an inhibitor of

angiogenesis. Proc Natl Acad Sci U S A 91, 4082-4085.

16. Mori, S., Ueda, T., Kuratsu, S., Hosono, N., Izawa, K., and Uchida, A. (1995). Suppression of

pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 61,

148-152.

17. Weinstat-Saslow, D. L., Zabrenetzky, V. S., VanHoutte, K., Frazier, W. A., Roberts, D. D., and

Steeg, P. S. (1994). Transfection of thrombospondin 1 complementary DNA into a human breast

carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer

Res 54, 6504-6511.

18. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R.,

Olsen, B. R., and Folkman, J. (1997). Endostatin: an endogenous inhibitor of angiogenesis and

tumor growth. Cell 88, 277-285.

19. Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks,

W., Witte, L., Wu, Y., Hicklin, D., Zhu, Z., Hackett, N. R., Crystal, R. G., Moore, M. A., Hajjar, K. A.,

Manova, K., Benezra, R., and Rafii, S. (2001). Impaired recruitment of bone-marrow-derived


128

endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7,

1194-1201.

20. Hendrix, M. J. C., Seftor, E. A., Hess, A. R., and Seftor, R. E. B. Vasculogenic mimicry and tumour-

cell plasticity: lessons from melanoma. Nat.Med. 3, 411-421. 2003.

Ref Type: Generic

21. Conway, E. M., Collen, D., and Carmeliet, P. (2001). Molecular mechanisms of blood vessel growth.

Cardiovasc.Res 49, 507-521.

22. Bergersm, G. and Benjamin, L. E. Tumorigenesis and the angiognic switch. Nat.Med. 3, 401-410.

2003.

Ref Type: Generic

23. Ausprunk, D. H. and Folkman, J. (1977). Migration and proliferation of endothelial cells in preformed

and newly formed blood vessels during tumor angiogenesis. Microvasc.Res 14, 53-65.

24. Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K., and McDonald, D. M. (2002).

Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160,

985-1000.

25. Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., and Jain, R. K.

(1998). Regulation of transport pathways in tumor vessels: role of tumor type and

microenvironment. Proc Natl Acad Sci U S A 95, 4607-4612.

26. Jakeman, L. B., Armanini, M., Phillips, H. S., and Ferrara, N. (1993). Developmental expression of

binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role

for this protein in vasculogenesis and angiogenesis. Endocrinology 133, 848-859.

27. Senger, D. R., Van de, W. L., Brown, L. F., Nagy, J. A., Yeo, K. T., Yeo, T. K., Berse, B., Jackman,

R. W., Dvorak, A. M., and Dvorak, H. F. (1993). Vascular permeability factor (VPF, VEGF) in tumor

biology. Cancer Metastasis Rev 12, 303-324.

28. Achen, M. G. and Stacker, S. A. (1998). The vascular endothelial growth factor family; proteins

which guide the development of the vasculature. Int J Exp Pathol 79, 255-265.

29. Tammela, T., Enholm, B., Alitalo, K., and Paavonen, K. (2005). The biology of vascular endothelial

growth factors. Cardiovascular Research 65, 550-563.

30. Korhonen, J., Partanen, J., Armstrong, E., Vaahtokari, A., Elenius, K., Jalkanen, M., and Alitalo, K.

(1992). Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during

neovascularization. Blood 80, 2548-2555.

31. Davis, S., Aldrich, T. H., Jones, P. F., Acheson, A., Compton, D. L., Jain, V., Ryan, T. E., Bruno, J.,

Radziejewski, C., Maisonpierre, P. C., and Yancopoulos, G. D. (1996). Isolation of angiopoietin-1, a

ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87, 1161-1169.

32. Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C.,

Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., Daly, T. J., Davis, S., Sato, T. N., and

Yancopoulos, G. D. (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo

angiogenesis. Science 277, 55-60.

33. Valenzuela, D. M., Griffiths, J. A., Rojas, J., Aldrich, T. H., Jones, P. F., Zhou, H., McClain, J.,

Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Huang, T., Papadopoulos, N., Maisonpierre, P. C.,

Davis, S., and Yancopoulos, G. D. (1999). Angiopoietins 3 and 4: diverging gene counterparts in

mice and humans. Proc Natl Acad Sci U S A 96, 1904-1909.

34. Papapetropoulos, A., Fulton, D., Mahboubi, K., Kalb, R. G., O'Connor, D. S., Li, F., Altieri, D. C.,

and Sessa, W. C. (2000). Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin

Pathway. J.Biol.Chem. 275, 9102-9105.


129

35. Zhang, L., Yang, N., Park, J. W., Katsaros, D., Fracchioli, S., Cao, G., O'Brien-Jenkins, A., Randall,

T. C., Rubin, S. C., and Coukos, G. (2003). Tumor-derived vascular endothelial growth factor up-

regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting

angiogenesis in ovarian cancer. Cancer Res 63, 3403-3412.

36. Xu, Y., Liu, Y. J., and Yu, Q. (2004). Angiopoietin-3 inhibits pulmonary metastasis by inhibiting

tumor angiogenesis. Cancer Res 64, 6119-6126.

37. Yamakawa, M., Liu, L. X., Date, T., Belanger, A. J., Vincent, K. A., Akita, G. Y., Kuriyama, T.,

Cheng, S. H., Gregory, R. J., and Jiang, C. (2003). Hypoxia-inducible factor-1 mediates activation of

cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 93, 664-673.

38. Friesel, R. E. and Maciag, T. (1995). Molecular mechanisms of angiogenesis: fibroblast growth

factor signal transduction. FASEB J 9, 919-925.

39. Schreiber, A. B., Winkler, M. E., and Derynck, R. (1986). Transforming growth factor-alpha: a more

potent angiogenic mediator than epidermal growth factor. Science 232, 1250-1253.

40. Leibovich, S. J., Polverini, P. J., Shepard, H. M., Wiseman, D. M., Shively, V., and Nuseir, N.

(1987). Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature

329, 630-632.

41. Moghaddam A. Thymidine phosphorylase/platelet endothelial cell derived growth factor: an

angogenic enzyme. Tumor Angiogenesis, Oxford University Press , 251-260. 1997.

Ref Type: Generic

42. Hu, G., Riordan, J. F., and Vallee, B. L. (1994). Angiogenin promotes invasiveness of cultured

endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci U S A 91,

12096-12100.

43. Desbaillets, I., Diserens, A. C., Tribolet, N., Hamou, M. F., and Van Meir, E. G. (1997). Upregulation

of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation,

chemotaxis, and angiogenesis. J Exp Med 186, 1201-1212.

44. Gullino, P. M. (1995). Prostaglandins and gangliosides of tumor microenvironment: their role in

angiogenesis. Acta Oncol 34, 439-441.

45. Kull, F. C., Jr., Brent, D. A., Parikh, I., and Cuatrecasas, P. (1987). Chemical identification of a

tumor-derived angiogenic factor. Science 236, 843-845.

46. Sierra-Honigmann, M. R., Nath, A. K., Murakami, C., Garc&iacute, a-Carde&ntilde, a, G.,

Papapetropoulos, A., Sessa, W. C., Madge, L. A., Schechner, J. S., Schwabb, M. B., Polverini, P.

J., and Flores-Riveros, J. R. (1998). Biological Action of Leptin as an Angiogenic Factor. Science

281, 1683-1686.

47. Nyberg, P., Xie, L., and Kalluri, R. (2005). Endogenous inhibitors of angiogenesis. Cancer Res 65,

3967-3979.

48. Lartigau, E., Le Ridant, A. M., Lambin, P., Weeger, P., Martin, L., Sigal, R., Lusinchi, A., Luboinski,

B., Eschwege, F., and Guichard, M. (1993). Oxygenation of head and neck tumors. Cancer 71,

2319-2325.

49. Lartigau, E., Randrianarivelo, H., Avril, M. F., Margulis, A., Spatz, A., Eschwege, F., and Guichard,

M. (1997). Intratumoral oxygen tension in metastatic melanoma. Melanoma Res 7, 400-406.

50. Zygmunt, A., Tedesco, V. C., Udho, E., and Krucher, N. A. (2002). Hypoxia stimulates p16

expression and association with cdk4. Exp.Cell Res 278, 53-60.

51. Gardner, L. B., Li, Q., Park, M. S., Flanagan, W. M., Semenza, G. L., and Dang, C. V. (2001).

Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression. J.Biol.Chem. 276, 7919-

7926.


130

52. To, K. K., Koshiji, M., Hammer, S., and Huang, L. E. (2005). Genetic instability: the dark side of the

hypoxic response. Cell Cycle 4, 881-882.

53. Dong, Z., Wang, J. Z., Yu, F., and Venkatachalam, M. A. (2003). Apoptosis-Resistance of Hypoxic

Cells: Multiple Factors Involved and a Role for IAP-2. Am J Pathol 163, 663-671.

54. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., and

Dewhirst, M. W. (1996). Tumor oxygenation predicts for the likelihood of distant metastases in

human soft tissue sarcoma. Cancer Res 56, 941-943.

55. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. (1992). Vascular endothelial growth factor induced by

hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845.

56. Gray, M. J., Zhang, J., Ellis, L. M., Semenza, G. L., Evans, D. B., Watowich, S. S., and Gallick, G.

E. (2005). HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional

complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and

prostate carcinomas. Oncogene 24, 3110-3120.

57. Shie, J. L., Wu, G., Wu, J., Liu, F. F., Laham, R. J., Oettgen, P., and Li, J. (2004). RTEF-1, a novel

transcriptional stimulator of vascular endothelial growth factor in hypoxic endothelial cells. J Biol

Chem. 279, 25010-25016.

58. Mizukami, Y., Li, J., Zhang, X., Zimmer, M. A., Iliopoulos, O., and Chung, D. C. (2004). Hypoxia-

Inducible Factor-1-Independent Regulation of Vascular Endothelial Growth Factor by Hypoxia in

Colon Cancer. Cancer Res 64, 1765-1772.

59. White, F. C., Carroll, S. M., and Kamps, M. P. (1995). VEGF mRNA is reversibly stabilized by

hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines. Growth Factors

12, 289-301.

60. Gerber, H. P., Condorelli, F., Park, J., and Ferrara, N. (1997). Differential Transcriptional Regulation

of the Two Vascular Endothelial Growth Factor Receptor Genes. Flt-1, BUT NOT Flk-1/KDR, IS UP-

REGULATED BY HYPOXIA. J.Biol.Chem. 272, 23659-23667.

61. Ozawa, K., Tsukamoto, Y., Hori, O., Kitao, Y., Yanagi, H., Stern, D. M., and Ogawa, S. (2001).

Regulation of Tumor Angiogenesis by Oxygen-regulated Protein 150, an Inducible Endoplasmic

Reticulum Chaperone. Cancer Res 61, 4206-4213.

62. Abdulmalek, K., Ashur, F., Ezer, N., Ye, F., Magder, S., and Hussain, S. N. (2001). Differential

expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats. Am.J.Physiol

Lung Cell Mol Physiol 281, L582-L590.

63. Hartmann, A., Kunz, M., Kostlin, S., Gillitzer, R., Toksoy, A., Brocker, E. B., and Klein, C. E. (1999).

Hypoxia-induced Up-Regulation of Angiogenin in Human Malignant Melanoma. Cancer Res 59,

1578-1583.

64. Griffiths, L., Dachs, G. U., Bicknell, R., Harris, A. L., and Stratford, I. J. (1997). The influence of

oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine

phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 57, 570-572.

65. Kitazono, M., Takebayashi, Y., Ishitsuka, K., Takao, S., Tani, A., Furukawa, T., Miyadera, K.,

Yamada, Y., Aikou, T., and Akiyama, S. (1998). Prevention of hypoxia-induced apoptosis by the

angiogenic factor thymidine phosphorylase. Biochem Biophys.Res Commun. 253, 797-803.

66. Chen, E. Y., Mazure, N. M., Cooper, J. A., and Giaccia, A. J. (2001). Hypoxia activates a platelet-

derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen

synthase kinase-3 inactivation. Cancer Res 61, 2429-2433.


131

67. Graham, C. H., Forsdike, J., Fitzgerald, C. J., and Macdonald-Goodfellow, S. (1999). Hypoxia-

mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor

expression. Int J Cancer 80, 617-623.

68. Ridgway, P. F., Ziprin, P., Alkhamesi, N., Paraskeva, P. A., Peck, D. H., and Darzi, A. W. (2005).

Hypoxia augments gelatinase activity in a variety of adenocarcinomas in vitro. J Surg.Res 124, 180-

186.

69. Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E., Xu, H. J., Benedict, W., and Bouck, N. P.

(1999). Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis. Science 285, 245-

248.

70. Wu, P., Yonekura, H., Li, H., Nozaki, I., Tomono, Y., Naito, I., Ninomiya, Y., and Yamamoto, H.

(2001). Hypoxia down-regulates endostatin production by human microvascular endothelial cells

and pericytes. Biochem.Biophys.Res Commun. 288, 1149-1154.

71. Cummins, E. P. and Taylor, C. T. (2005). Hypoxia-responsive transcription factors. Pflugers Arch.

450, 363-371.

72. Abate, C., Patel, L., Rauscher, F. J., III, and Curran, T. (1990). Redox regulation of fos and jun

DNA-binding activity in vitro. Science 249, 1157-1161.

73. Ausserer, W. A., Bourrat-Floeck, B., Green, C. J., Laderoute, K. R., and Sutherland, R. M. (1994).

Regulation of c-jun expression during hypoxic and low-glucose stress. Mol Cell Biol 14, 5032-5042.

74. Fantozzi, I., Zhang, S., Platoshyn, O., Remillard, C. V., Cowling, R. T., and Yuan, J. X. J. (2003).

Hypoxia increases AP-1 binding activity by enhancing capacitative Ca2+ entry in human pulmonary

artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 285, L1233-L1245.

75. Laderoute, K. R. (2005). The interaction between HIF-1 and AP-1 transcription factors in response

to low oxygen. Semin Cell Dev Biol 16, 502-513.

76. Marden, N. Y., Fiala-Beer, E., Xiang, S. H., and Murray, M. (2003). Role of activator protein-1 in the

down-regulation of the human CYP2J2 gene in hypoxia. Biochem J 373 , 669-680.

77. May, M. J. and Ghosh, S. (1998). Signal transduction through NF-kappa B. Immunol Today 19 , 80-

88.

78. Koong, A. C., Chen, E. Y., Mivechi, N. F., Denko, N. C., Stambrook, P., and Giaccia, A. J. (1994).

Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and

does not involve MAP kinase (ERK1 or ERK2). Cancer Res 54, 5273-5279.

79. Toledano, M. B. and Leonard, W. J. (1991). Modulation of transcription factor NF-kappa B binding

activity by oxidation-reduction in vitro. Proc Natl Acad Sci U S A 88, 4328-4332.

80. Aggarwal, B. B., Takada, Y., Shishodia, S., Gutierrez, A. M., Oommen, O. V., Ichikawa, H., Baba,

Y., and Kumar, A. (2004). Nuclear transcription factor NF-kappa B: role in biology and medicine.

Indian J Exp Biol 42, 341-353.

81. Rahmani, M., Peron, P., Weitzman, J., Bakiri, L., Lardeux, B., and Bernuau, D. (2001). Functional

cooperation between JunD and NF-kappaB in rat hepatocytes. Oncogene 20, 5132-5142.

82. Miki, N., Ikuta, M., and Matsui, T. (2004). Hypoxia-induced Activation of the Retinoic Acid Receptor-

related Orphan Receptor {alpha}4 Gene by an Interaction between Hypoxia-inducible Factor-1 and

Sp1. J.Biol.Chem. 279, 15025-15031.

83. Petrella, B. L., Lohi, J., and Brinckerhoff, C. E. (2005). Identification of membrane type-1 matrix

metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell

carcinoma. Oncogene 24, 1043-1052.


132

84. Xu, Q., Ji, Y. S., and Schmedtje, J. F., Jr. (2000). Sp1 increases expression of cyclooxygenase-2 in

hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure.

J Biol Chem. 275, 24583-24589.

85. Lichtlen, P. and Schaffner, W. (2001). The "metal transcription factor" MTF-1: biological facts and

medical implications. Swiss.Med Wkly. 131, 647-652.

86. Cai, L., Satoh, M., Tohyama, C., and Cherian, M. G. (1999). Metallothionein in radiation exposure:

its induction and protective role. Toxicology 132, 85-98.

87. van Lookeren, C. M., Thibodeaux, H., van Bruggen, N., Cairns, B., Gerlai, R., Palmer, J. T.,

Williams, S. P., and Lowe, D. G. (1999). Evidence for a protective role of metallothionein-1 in focal

cerebral ischemia. Proc Natl Acad Sci U S A 96, 12870-12875.

88. Lazo, J. S., Kondo, Y., Dellapiazza, D., Michalska, A. E., Choo, K. H., and Pitt, B. R. (1995).

Enhanced sensitivity to oxidative stress in cultured embryonic cells from transgenic mice deficient in

metallothionein I and II genes. J Biol Chem. 270, 5506-5510.

89. Murphy, B. J., Andrews, G. K., Bittel, D., Discher, D. J., McCue, J., Green, C. J., Yanovsky, M.,

Giaccia, A., Sutherland, R. M., Laderoute, K. R., and Webster, K. A. (1999). Activation of

metallothionein gene expression by hypoxia involves metal response elements and metal

transcription factor-1. Cancer Res 59, 1315-1322.

90. Murphy, B. J., Sato, B. G., Dalton, T. P., and Laderoute, K. R. (2005). The metal-responsive

transcription factor-1 contributes to HIF-1 activation during hypoxic stress. Biochem Biophys.Res

Commun.

91. McCluggage, W. G., Maxwell, P., Hamilton, P. W., and Jasani, B. (1999). High metallothionein

expression is associated with features predictive of aggressive behaviour in endometrial carcinoma.

Histopathology 34, 51-55.

92. Greijer, A. E., van der, G. P., Kemming, D., Shvarts, A., Semenza, G. L., Meijer, G. A., van de Wiel,

M. A., Belien, J. A., van Diest, P. J., and Van Der, W. E. (2005). Up-regulation of gene expression

by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206, 291-304.

93. Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., and Maity, A. (2001). Regulation of glut1 mRNA by

Hypoxia-inducible Factor-1. INTERACTION BETWEEN H-ras AND HYPOXIA. J.Biol.Chem. 276,

9519-9525.

94. Minchenko, A., Leshchinsky, I., Opentanova, I., Sang, N., Srinivas, V., Armstead, V., and Caro, J.

(2002). Hypoxia-inducible Factor-1-mediated Expression of the 6-Phosphofructo-2-kinase/fructose-

2,6-bisphosphatase-3 (PFKFB3) Gene. ITS POSSIBLE ROLE IN THE WARBURG EFFECT.

J.Biol.Chem. 277, 6183-6187.

95. Acker, T. and Plate, K. H. (2002). A role for hypoxia and hypoxia-inducible transcription factors in

tumor physiology. J.Mol Med. 80, 562-575.

96. Varma, S. and Cohen, H. J. (1997). Co-transactivation of the 3' erythropoietin hypoxia inducible

enhancer by the HIF-1 protein. Blood Cells Mol Dis. 23, 169-176.

97. Liu, L. X., Lu, H., Luo, Y., Date, T., Belanger, A. J., Vincent, K. A., Akita, G. Y., Goldberg, M.,

Cheng, S. H., Gregory, R. J., and Jiang, C. (2002). Stabilization of vascular endothelial growth

factor mRNA by hypoxia- inducible factor 1. Biochem.Biophys.Res Commun. 291, 908-914.

98. Akakura, N., Kobayashi, M., Horiuchi, I., Suzuki, A., Wang, J., Chen, J., Niizeki, H., Kawamura, K.,

Hosokawa, M., and Asaka, M. (2001). Constitutive expression of hypoxia-inducible factor-1alpha

renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation.

Cancer Res 61, 6548-6554.


133

99. Wang, G. L., Jiang, B., Rue, E. A., and Semenza, G. L. (1995). Hypoxia-Inducible Factor 1 is a

Basic-Helix-Loop-Helix-PAS Heterodimer Regulated by Cellular O2 Tension. PNAS 92, 5510-5514.

100. Jiang, B. H., Rue, E., Wang, G. L., Roe, R., and Semenza, G. L. (1996). Dimerization, DNA binding,

and transactivation properties of hypoxia-inducible factor 1. J Biol Chem. 271, 17771-17778.

101. Yang, J., Zhang, L., Erbel, P. J., Gardner, K. H., Ding, K., Garcia, J. A., and Bruick, R. K. (2005).

Functions of the Per/ARNT/Sim Domains of the Hypoxia-inducible Factor. J Biol Chem. 280, 36047-

36054.

102. Chapman-Smith, A., Lutwyche, J. K., and Whitelaw, M. L. (2004). Contribution of the Per/Arnt/Sim

(PAS) Domains to DNA Binding by the Basic Helix-Loop-Helix PAS Transcriptional Regulators.

J.Biol.Chem. 279, 5353-5362.

103. Pugh, C. W., O'Rourke, J. F., Nagao, M., Gleadle, J. M., and Ratcliffe, P. J. (1997). Activation of

hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem.

272, 11205-11214.

104. Luo, J. C. and Shibuya, M. (2001). A variant of nuclear localization signal of bipartite-type is

required for the nuclear translocation of hypoxia inducible factors (1alpha, 2alpha and 3alpha).

Oncogene 20, 1435-1444.

105. Hankinson, O. (1995). The aryl hydrocarbon receptor complex. Annu.Rev Pharmacol Toxicol. 35,

307-340.

106. Woods, S. L. and Whitelaw, M. L. (2002). Differential Activities of Murine Single Minded 1 (SIM1)

and SIM2 on a Hypoxic Response Element. CROSS-TALK BETWEEN BASIC HELIX-LOOP-

HELIX/Per-Arnt-Sim HOMOLOGY TRANSCRIPTION FACTORS. J.Biol.Chem. 277, 10236-10243.

107. Lee, K. H., Park, J. W., and Chun, Y. S. (2004). Non-hypoxic transcriptional activation of the aryl

hydrocarbon receptor nuclear translocator in concert with a novel hypoxia-inducible factor-1alpha

isoform. Nucl.Acids.Res. 32, 5499-5511.

108. Maltepe, E., Keith, B., Arsham, A. M., Brorson, J. R., and Simon, M. C. (2000). The role of ARNT2

in tumor angiogenesis and the neural response to hypoxia. Biochem.Biophys.Res Commun. 273,

231-238.

109. Liu, C., Goshu, E., Wells, A., and Fan, C. M. (2003). Identification of the downstream targets of

SIM1 and ARNT2, a pair of transcription factors essential for neuroendocrine cell differentiation. J

Biol Chem. 278, 44857-44867.

110. Takahata, S., Sogawa, K., Kobayashi, A., Ema, M., Mimura, J., Ozaki, N., and Fujii-Kuriyama, Y.

(1998). Transcriptionally active heterodimer formation of an Arnt-like PAS protein, Arnt3, with HIF-

1a, HLF, and clock. Biochem Biophys.Res Commun. 248, 789-794.

111. Pollenz, R. S., Davarinos, N. A., and Shearer, T. P. (1999). Analysis of aryl hydrocarbon receptor-

mediated signaling during physiological hypoxia reveals lack of competition for the aryl hydrocarbon

nuclear translocator transcription factor. Mol Pharmacol 56, 1127-1137.

112. Minet, E., Ernest, I., Michel, G., Roland, I., Remacle, J., Raes, M., and Michiels, C. (1999). HIF1A

gene transcription is dependent on a core promoter sequence encompassing activating and

inhibiting sequences located upstream from the transcription initiation site and cis elements located

within the 5'UTR. Biochem Biophys.Res Commun. 261, 534-540.

113. Salceda, S. and Caro, J. (1997). Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly

degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by

hypoxia depends on redox-induced changes. J Biol Chem. 272, 22642-22647.

114. Ohh, M. and Kaelin, W. G., Jr. (1999). The von Hippel-Lindau tumour suppressor protein: new

perspectives. Mol Med.Today 5, 257-263.


134

115. Tanimoto, K., Makino, Y., Pereira, T., and Poellinger, L. (2000). Mechanism of regulation of the

hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19,

4298-4309.

116. Groulx, I. and Lee, S. (2002). Oxygen-Dependent Ubiquitination and Degradation of Hypoxia-

Inducible Factor Requires Nuclear-Cytoplasmic Trafficking of the von Hippel-Lindau Tumor

Suppressor Protein. Mol.Cell.Biol. 22, 5319.

117. Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S.,

and Kaelin, W. G., Jr. (2001). HIFalpha Targeted for VHL-Mediated Destruction by Proline

Hydroxylation: Implications for O2 Sensing. Science 292, 464-468.

118. Jaakkola, P., Mole, D. R., Tian, Y. M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. v.,

Hebestreit, H. F., Mukherji, M., Schofield, C. J., Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J.

(2001). Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated

Prolyl Hydroxylation. Science 292, 468-472.

119. Hon, W. C., Wilson, M. I., Harlos, K., Claridge, T. D., Schofield, C. J., Pugh, C. W., Maxwell, P. H.,

Ratcliffe, P. J., Stuart, D. I., and Jones, E. Y. (2002). Structural basis for the recognition of

hydroxyproline in HIF-1 alpha by pVHL. Nature 417, 975-978.

120. Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J. (2001). Independent

function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl

hydroxylation. EMBO J. 20, 5197-5206.

121. Epstein, A. C., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji,

M., Metzen, E., Wilson, M. I., Dhanda, A., Tian, Y. M., Masson, N., Hamilton, D. L., Jaakkola, P.,

Barstead, R., Hodgkin, J., Maxwell, P. H., Pugh, C. W., Schofield, C. J., and Ratcliffe, P. J. (2001).

C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by

prolyl hydroxylation. Cell 107, 43-54.

122. McNeill, L. A., Hewitson, K. S., Gleadle, J. M., Horsfall, L. E., Oldham, N. J., Maxwell, P. H., Pugh,

C. W., Ratcliffe, P. J., and Schofield, C. J. (2002). The use of dioxygen by HIF prolyl hydroxylase

(PHD1). Bioorg.Med.Chem.Lett. 12, 1547-1550.

123. Huang, J., Zhao, Q., Mooney, S. M., and Lee, F. S. (2002). Sequence determinants in hypoxia-

inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3.

J.Biol.Chem. 277, 39792-39800.

124. Kageyama, Y., Koshiji, M., To, K. K. W., Tian, Y. M., Ratcliffe, P. J., and Huang, L. E. (2004). Leu-

574 of human HIF-1α is a molecular determinant of prolyl hydroxylation. FASEB J. 03-

1233fje.

125. Esteban, M. A. and Maxwell, P. H. (2005). HIF, a missing link between metabolism and cancer. Nat

Med 11, 1047-1048.

126. Knowles, H. J., Raval, R. R., Harris, A. L., and Ratcliffe, P. J. (2003). Effect of ascorbate on the

activity of hypoxia-inducible factor in cancer cells. Cancer Res 63 , 1764-1768.

127. Clarke, H. and Pallister, C. J. (2005). The impact of anaemia on outcome in cancer. Clin Lab

Haematol 27, 1-13.

128. Hirsila, M., Koivunen, P., Gunzler, V., Kivirikko, K. I., and Myllyharju, J. (2003). Characterization of

the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor. J.Biol.Chem. 278,

30772-30780.

129. Erez, N., Stambolsky, P., Shats, I., Milyavsky, M., Kachko, T., and Rotter, V. (2004). Hypoxia-

dependent regulation of PHD1: cloning and characterization of the human PHD1/EGLN2 gene

promoter. FEBS Letters 567, 311-315.


135

130. Marxsen, J. H., Stengel, P., Doege, K., Heikkinen, P., Jokilehto, T., Wagner, T., Jelkmann, W.,

Jaakkola, P., and Metzen, E. (2004). Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by

induction of HIF-alpha-prolyl-4-hydroxylases. Biochem J 381, 761-767.

131. Aprelikova, O., Chandramouli, G. V., Wood, M., Vasselli, J. R., Riss, J., Maranchie, J. K., Linehan,

W. M., and Barrett, J. C. (2004). Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.

J Cell Biochem 92, 491-501.

132. Berra, E., Richard, D. E., Gothie, E., and Pouyssegur, J. (2001). HIF-1-dependent transcriptional

activity is required for oxygen-mediated HIF-1[alpha] degradation. FEBS Letters 491, 85-90.

133. Nakayama, K., Frew, I. J., Hagensen, M., Skals, M., Habelhah, H., Bhoumik, A., Kadoya, T.,

Erdjument-Bromage, H., Tempst, P., Frappell, P. B., Bowtell, D. D., and Ronai, Z. (2004). Siah2

regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates

physiological responses to hypoxia. Cell 117, 941-952.

134. Appelhoff, R. J., Tian, Y. M., Raval, R. R., Turley, H., Harris, A. L., Pugh, C. W., Ratcliffe, P. J., and

Gleadle, J. M. (2004). Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the

regulation of hypoxia-inducible factor. J Biol Chem. 279, 38458-38465.

135. Tuckerman, J. R., Zhao, Y., Hewitson, K. S., Tian, Y. M., Pugh, C. W., Ratcliffe, P. J., and Mole, D.

R. (2004). Determination and comparison of specific activity of the HIF-prolyl hydroxylases. FEBS

Letters 576, 145-150.

136. Chan, D. A., Sutphin, P. D., Yen, S. E., and Giaccia, A. J. (2005). Coordinate regulation of the

oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol 25, 6415-

6426.

137. Metzen, E., Berchner-Pfannschmidt, U., Stengel, P., Marxsen, J. H., Stolze, I., Klinger, M., Huang,

W. Q., Wotzlaw, C., Hellwig-Burgel, T., Jelkmann, W., Acker, H., and Fandrey, J. (2003).

Intracellular localisation of human HIF-1{alpha} hydroxylases: implications for oxygen sensing. J

Cell Sci 116, 1319.

138. Baek, J. H., Mahon, P. C., Oh, J., Kelly, B., Krishnamachary, B., Pearson, M., Chan, D. A., Giaccia,

A. J., and Semenza, G. L. (2005). OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl

hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol Cell 17, 503-512.

139. Berra, E., Benizri, E., Ginouves, A., Volmat, V., Roux, D., and Pouyssegur, J. (2003). HIF prolyl-

hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1{alpha} in normoxia.

EMBO J. 22, 4082-4090.

140. Madden, S. L., Galella, E. A., Riley, D., Bertelsen, A. H., and Beaudry, G. A. (1996). Induction of cell

growth regulatory genes by p53. Cancer Res 56, 5384-5390.

141. Seth, P., Krop, I., Porter, D., and Polyak, K. (2002). Novel estrogen and tamoxifen induced genes

identified by SAGE (Serial Analysis of Gene Expression). Oncogene 21, 836-843.

142. Jeong, J. W., Bae, M. K., Ahn, M. Y., Kim, S. H., Sohn, T. K., Bae, M. H., Yoo, M. A., Song, E. J.,

Lee, K. J., and Kim, K. W. (2002). Regulation and destabilization of HIF-1alpha by ARD1-mediated

acetylation. Cell 111, 709-720.

143. Bilton, R., Mazure, N., Trottier, E., Hattab, M., Dery, M. A., Richard, D. E., Pouyssegur, J., and

Brahimi-Horn, M. C. (2005). Arrest-defective-1 protein, an acetyltransferase, does not alter stability

of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J Biol Chem. 280,

31132-31140.

144. Arnesen, T., Kong, X., Evjenth, R., Gromyko, D., Varhaug, J. E., Lin, Z., Sang, N., Caro, J., and

Lillehaug, J. R. (2005). Interaction between HIF-1alpha (ODD) and hARD1 does not induce

acetylation and destabilization of HIF-1alpha. FEBS Lett. 579, 6428-6432.


136

145. Fisher, T. S., Etages, S. D., Hayes, L., Crimin, K., and Li, B. (2005). Analysis of ARD1 function in

hypoxia response using retroviral RNA interference. J Biol Chem. 280, 17749-17757.

146. Li, L. and Deng, X. W. (2003). The COP9 signalosome: an alternative lid for the 26S proteasome?

Trends Cell Biol 13, 507-509.

147. Bemis, L., Chan, D. A., Finkielstein, C. V., Qi, L., Sutphin, P. D., Chen, X., Stenmark, K., Giaccia, A.

J., and Zundel, W. (2004). Distinct aerobic and hypoxic mechanisms of HIF-{alpha} regulation by

CSN5. Genes Dev. 18, 739-744.

148. Li, Z., Wang, D., Messing, E. M., and Wu, G. (2005). VHL protein-interacting deubiquitinating

enzyme 2 deubiquitinates and stabilizes HIF-1alpha. EMBO Rep. 6, 373-378.

149. Mekhail, K., Gunaratnam, L., Bonicalzi, M. E., and Lee, S. (2004). HIF activation by pH-dependent

nucleolar sequestration of VHL. Nat Cell Biol 6, 642-647.

150. Karhausen, J., Kong, T., Narravula, S., and Colgan, S. P. (2005). Induction of the von Hippel-Lindau

tumor suppressor gene by late hypoxia limits HIF-1 expression. J Cell Biochem 95, 1264-1275.

151. Bae, S. H., Jeong, J. W., Park, J. A., Kim, S. H., Bae, M. K., Choi, S. J., and Kim, K. W. (2004).

Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochem Biophys.Res

Commun. 324, 394-400.

152. Seeler, J. S. and Dejean, A. (2003). Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol

4, 690-699.

153. Shao, R., Zhang, F. P., Tian, F., Anders, F. P., Wang, X., Sjoland, H., and Billig, H. (2004). Increase

of SUMO-1 expression in response to hypoxia: direct interaction with HIF-1alpha in adult mouse

brain and heart in vivo. FEBS Lett. 569, 293-300.

154. Tojo, M., Matsuzaki, K., Minami, T., Honda, Y., Yasuda, H., Chiba, T., Saya, H., Fujii-Kuriyama, Y.,

and Nakao, M. (2002). The aryl hydrocarbon receptor nuclear transporter is modulated by the

SUMO-1 conjugation system. J Biol Chem. 277, 46576-46585.

155. Koumenis, C., Alarcon, R., Hammond, E., Sutphin, P., Hoffman, W., Murphy, M., Derr, J., Taya, Y.,

Lowe, S. W., Kastan, M., and Giaccia, A. (2001). Regulation of p53 by hypoxia: dissociation of

transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21,

1297-1310.

156. Pan, Y., Oprysko, P. R., Asham, A. M., Koch, C. J., and Simon, M. C. (2004). p53 cannot be

induced by hypoxia alone but responds to the hypoxic microenvironment. Oncogene 23, 4975-4983.

157. Kaluzova, M., Kaluz, S., Lerman, M. I., and Stanbridge, E. J. (2004). DNA damage is a prerequisite

for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the

hypoxia marker carbonic anhydrase IX. Mol Cell Biol 24, 5757-5766.

158. Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E.,

Madan, A., Semenza, G. L., and Bedi, A. (2000). Regulation of tumor angiogenesis by p53-induced

degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14, 34-44.

159. Suzuki, H., Tomida, A., and Tsuruo, T. (2001). Dephosphorylated hypoxia-inducible factor 1alpha

as a mediator of p53- dependent apoptosis during hypoxia. Oncogene 20, 5779-5788.

160. Bae, M. K., Ahn, M. Y., Jeong, J. W., Bae, M. H., Lee, Y. M., Bae, S. K., Park, J. W., Kim, K. R., and

Kim, K. W. (2001). Jab1 Interacts Directly with HIF-1alpha and Regulates Its Stability. J.Biol.Chem.

277, 9-12.

161. Hansson, L. O., Friedler, A., Freund, S., Rudiger, S., and Fersht, A. R. (2002). Two sequence motifs

from HIF-1alpha bind to the DNA-binding site of p53. PNAS 99, 10305-10309.

162. Chen, D., Li, M., Luo, J., and Gu, W. (2003). Direct Interactions between HIF-1alpha and Mdm2

Modulate p53 Function. J.Biol.Chem. 278, 13595.


137

163. Schmid, T., Zhou, J., Kohl, R., and Brune, B. (2004). p300 relieves p53-evoked transcriptional

repression of hypoxia-inducible factor-1 (HIF-1). Biochem J 380, 289-295.

164. Nieminen, A. L., Qanungo, S., Schneider, E. A., Jiang, B. H., and Agani, F. H. (2005). Mdm2 and

HIF-1alpha interaction in tumor cells during hypoxia. J Cell Physiol 204 , 364-369.

165. Zhang, L. and Hill, R. P. (2004). Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in

KHT cells and increasing resistance to apoptosis. Cancer Res 64, 4180-4189.

166. Yoo, Y. G., Yeo, M. G., Kim, D. K., Park, H., and Lee, M. O. (2004). Novel Function of Orphan

Nuclear Receptor Nur77 in Stabilizing Hypoxia-inducible Factor-1{alpha}. J.Biol.Chem. 279, 53365-

53373.

167. An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., and Neckers, L. M. (1998).

Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392, 405-408.

168. Wenger, R. H., Camenisch, G., Desbaillets, I., Chilov, D., and Gassmann, M. (1998). Up-regulation

of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction. Cancer Res 58,

5678-5680.

169. Jiang, B. H., Semenza, G. L., Bauer, C., and Marti, H. H. (1996). Hypoxia-inducible factor 1 levels

vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 271, C1172-

C1180.

170. Schmid, T., Zhou, J., and Brune, B. (2004). HIF-1 and p53: communication of transcription factors

under hypoxia. J Cell Mol Med 8, 423-431.

171. Minet, E., Mottet, D., Michel, G., Roland, I., Raes, M., Remacle, J., and Michiels, C. (1999).

Hypoxia-induced activation of HIF-1: role of HIF-1[alpha]-Hsp90 interaction. FEBS Letters 460, 251-

256.

172. Isaacs, J. S., Jung, Y. J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., and Neckers, L. M. (2002).

Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1alpha -degradative

Pathway. J.Biol.Chem. 277, 29936-29944.

173. Hur, E., Kim, H. H., Choi, S. M., Kim, J. H., Yim, S., Kwon, H. J., Choi, Y., Kim, D. K., Lee, M. O.,

and Park, H. (2002). Reduction of hypoxia-induced transcription through the repression of hypoxia-

inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa

heat-shock protein inhibitor radicicol. Mol Pharmacol 62, 975-982.

174. Agani, F. H., Puchowicz, M., Chavez, J. C., Pichiule, P., and LaManna, J. (2002). Role of nitric

oxide in the regulation of HIF-1alpha expression during hypoxia. Am.J.Physiol Cell Physiol 283,

C178-C186.

175. Hagen, T., Taylor, C. T., Lam, F., and Moncada, S. (2003). Redistribution of Intracellular Oxygen in

Hypoxia by Nitric Oxide: Effect on HIF1{alpha}. Science 302, 1975-1978.

176. Palmer, L. A., Semenza, G. L., Stoler, M. H., and Johns, R. A. (1998). Hypoxia induces type II NOS

gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol 274, L212-L219.

177. Mateo, J., Garcia-Lecea, M., Cadenas, S., Hernandez, C., and Moncada, S. (2003). Regulation of

hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and -independent

pathways. Biochem J 376, 537-544.

178. Denko, N., Wernke-Dollries, K., Johnson, A. B., Hammond, E., Chiang, C. M., and Barton, M. C.

(2003). Hypoxia Actively Represses Transcription by Inducing Negative Cofactor 2 (Dr1/DrAP1) and

Blocking Preinitiation Complex Assembly. J.Biol.Chem. 278 , 5744.

179. Wouters, B. G., van den, B. T., Magagnin, M. G., Koritzinsky, M., Fels, D., and Koumenis, C.

(2005). Control of the hypoxic response through regulation of mRNA translation. Semin Cell Dev

Biol 16, 487-501.


138

180. Lang, K. J. D., Kappel, A., and Goodall, G. J. (2002). Hypoxia-inducible Factor-1alpha mRNA

Contains an Internal Ribosome Entry Site That Allows Efficient Translation during Normoxia and

Hypoxia. Mol.Biol.Cell 13, 1792.

181. Rossignol, F., Vache, C., and Clottes, E. (2002). Natural antisense transcripts of hypoxia-inducible

factor 1alpha are detected in different normal and tumour human tissues. Gene 299, 135-140.

182. Arany, Z., Huang, L. á., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg, M., Bunn, H. á., and

Livingston, D. (1996). An essential role for p300/CBP in the cellular response to hypoxia. PNAS 93,

12969-12973.

183. Carrero, P., Okamoto, K., Coumailleau, P., O'Brien, S., Tanaka, H., and Poellinger, L. (2000).

Redox-regulated recruitment of the transcriptional coactivators CREB- binding protein and SRC-1 to

hypoxia-inducible factor 1alpha. Mol Cell Biol. 20, 402-415.

184. Lando, D., Pongratz, I., Poellinger, L., and Whitelaw, M. L. (2000). A Redox Mechanism Controls

Differential DNA Binding Activities of Hypoxia-inducible Factor (HIF) 1alpha and the HIF-like Factor.

J.Biol.Chem. 275, 4618-4627.

185. McNeill, L. A., Hewitson, K. S., Claridge, T. D., Seibel, J. F., Horsfall, L. E., and Schofield, C. J.

(2002). Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the

beta-carbon of asparagine-803. Biochem J 367, 571-575.

186. Freedman, S. J., Sun, Z. Y., Poy, F., Kung, A. L., Livingston, D. M., Wagner, G., and Eck, M. J.

(2002). Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1alpha. PNAS 99,

5367-5372.

187. Linke, S., Stojkoski, C., Kewley, R. J., Booker, G. W., Whitelaw, M. L., and Peet, D. J. (2004).

Substrate Requirements of the Oxygen-sensing Asparaginyl Hydroxylase Factor-inhibiting Hypoxia-

inducible Factor. J.Biol.Chem. 279, 14391-14397.

188. Lancaster, D. E., McNeill, L. A., McDonough, M. A., Aplin, R. T., Hewitson, K. S., Pugh, C. W.,

Ratcliffe, P. J., and Schofield, C. J. (2004). Disruption of dimerization and substrate phosphorylation

inhibit factor inhibiting hypoxia-inducible factor (FIH) activity. Biochem J 383, 429-437.

189. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., and Whitelaw, M. L. (2002). Asparagine

Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch. Science 295, 858-861.

190. Koivunen, P., Hirsila, M., Gunzler, V., Kivirikko, K. I., and Myllyharju, J. (2004). Catalytic Properties

of the Asparaginyl Hydroxylase (FIH) in the Oxygen Sensing Pathway Are Distinct from Those of Its

Prolyl 4-Hydroxylases. J.Biol.Chem. 279, 9899-9904.

191. Koshiji, M., Kageyama, Y., Pete, E. A., Horikawa, I., Barrett, J. C., and Huang, L. E. (2004). HIF-

1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 23, 1949-1956.

192. Lee, C., Kim, S. J., Jeong, D. G., Lee, S. M., and Ryu, S. E. (2003). Structure of Human FIH-1

Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel-Lindau.

J.Biol.Chem. 278, 7558.

193. Sang, N., Fang, J., Srinivas, V., Leshchinsky, I., and Caro, J. (2002). Carboxyl-terminal

transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau

protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol 22, 2984-

2992.

194. Mahon, P. C., Hirota, K., and Semenza, G. L. (2001). FIH-1: a novel protein that interacts with HIF-

1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675-2686.

195. Li, Z., Wang, D., Na, X., Schoen, S. R., Messing, E. M., and Wu, G. (2003). The VHL protein

recruits a novel KRAB-A domain protein to repress HIF-1{alpha} transcriptional activity. EMBO J.

22, 1857.


139

196. Kato, H., Tamamizu-Kato, S., and Shibasaki, F. (2004). Histone deacetylase 7 associates with

hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem. 279, 41966-

41974.

197. Minet, E., Michel, G., Mottet, D., Raes, M., and Michiels, C. (2001). Transduction pathways involved

in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Radic.Biol.Med. 31, 847-855.

198. Sodhi, A., Montaner, S., Miyazaki, H., and Gutkind, J. S. (2001). MAPK and Akt act cooperatively

but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF.

Biochem.Biophys.Res Commun. 287, 292-300.

199. Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T., and Vogt, P. K. (2001). Phosphatidylinositol

3-kinase signaling controls levels of hypoxia- inducible factor 1. Cell Growth Differ. 12, 363-369.

200. Alvarez-Tejado, M., Alfranca, A., Aragones, J., Vara, A., Landazuri, M. O., and del Peso, L. (2002).

Lack of Evidence for the Involvement of the Phosphoinositide 3-Kinase/Akt Pathway in the

Activation of Hypoxia-inducible Factors by Low Oxygen Tension. J.Biol.Chem. 277, 13508-13517.

201. Arsham, A. M., Howell, J. J., and Simon, M. C. (2003). A Novel Hypoxia-inducible Factor-

independent Hypoxic Response Regulating Mammalian Target of Rapamycin and Its Targets.

J.Biol.Chem. 278, 29655-29660.

202. Tang, T. T.-L. and Lasky, L. A. (2003). The Forkhead Transcription Factor FOXO4 Induces the

Down-regulation of Hypoxia-inducible Factor 1{alpha} by a von Hippel-Lindau Protein-independent

Mechanism. J.Biol.Chem. 278, 30125-30135.

203. Zhou, J., Schmid, T., Frank, R., and Brune, B. (2004). PI3K/Akt Is Required for Heat Shock Proteins

to Protect Hypoxia-inducible Factor 1{alpha} from pVHL-independent Degradation. J.Biol.Chem.

279, 13506-13513.

204. Beitner-Johnson, D., Rust, R. T., Hsieh, T. C., and Millhorn, D. E. (2001). Hypoxia activates Akt and

induces phosphorylation of GSK-3 in PC12 cells. Cell Signal. 13, 23-27.

205. Mottet, D., Dumont, V., Deccache, Y., Demazy, C., Ninane, N., Raes, M., and Michiels, C. (2003).

Regulation of Hypoxia-inducible Factor-1{alpha} Protein Level during Hypoxic Conditions by the

Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase 3{beta} Pathway in HepG2 Cells.

J.Biol.Chem. 278, 31277-31285.

206. Hur, E., Chang, K. Y., Lee, E., Lee, S. K., and Park, H. (2001). Mitogen-activated protein kinase

kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability

of hypoxia-inducible factor-1alpha. Mol Pharmacol 59, 1216-1224.

207. Berra, E., Milanini, J., Richard, D. E., Le Gall, M., Vinals, F., Gothie, E., Roux, D., Pages, G., and

Pouyssegur, J. (2000). Signaling angiogenesis via p42/p44 MAP kinase and hypoxia.

Biochem.Pharmacol 60, 1171-1178.

208. Sang, N., Stiehl, D. P., Bohensky, J., Leshchinsky, I., Srinivas, V., and Caro, J. (2003). MAPK

Signaling Up-regulates the Activity of Hypoxia-inducible Factors by Its Effects on p300. J.Biol.Chem.

278, 14013.

209. Liu, C., Shi, Y., Han, Z., Pan, Y., Liu, N., Han, S., Chen, Y., Lan, M., Qiao, T., and Fan, D. (2003).

Suppression of the dual-specificity phosphatase MKP-1 enhances HIF-1 trans-activation and

increases expression of EPO. Biochemical and Biophysical Research Communications 312, 780-

786.

210. Conrad, P. W., Rust, R. T., Han, J., Millhorn, D. E., and Beitner-Johnson, D. (1999). Selective

activation of p38alpha and p38gamma by hypoxia. Role in regulation of cyclin D1 by hypoxia in

PC12 cells. J Biol Chem. 274, 23570-23576.


140

211. Le, Y. J. and Corry, P. M. (1999). Hypoxia-induced bFGF gene expression is mediated through the

JNK signal transduction pathway. Mol Cell Biochem 202, 1-8.

212. Lee, M., Hwang, J. T., Lee, H. J., Jung, S. N., Kang, I., Chi, S. G., Kim, S. S., and Ha, J. (2003).

AMP-activated Protein Kinase Activity Is Critical for Hypoxia-inducible Factor-1 Transcriptional

Activity and Its Target Gene Expression under Hypoxic Conditions in DU145 Cells. J.Biol.Chem.

278, 39653-39661.

213. Mottet, D., Ruys, S. P., Demazy, C., Raes, M., and Michiels, C. (2005). Role for casein kinase 2 in

the regulation of HIF-1 activity. Int J Cancer 117, 764-774.

214. Colavitti, R., Pani, G., Bedogni, B., Anzevino, R., Borrello, S., Waltenberger, J., and Galeotti, T.

(2002). Reactive Oxygen Species as Downstream Mediators of Angiogenic Signaling by Vascular

Endothelial Growth Factor Receptor-2/KDR. J.Biol.Chem. 277, 3101-3108.

215. Zulueta, J. J., Yu, F. S., Hertig, I. A., Thannickal, V. J., and Hassoun, P. M. (1995). Release of

hydrogen peroxide in response to hypoxia-reoxygenation: role of an NAD(P)H oxidase-like enzyme

in endothelial cell plasma membrane. Am J Respir.Cell Mol Biol 12, 41-49.

216. Osada, M., Imaoka, S., Sugimoto, T., Hiroi, T., and Funae, Y. (2002). NADPH-Cytochrome P-450

Reductase in the Plasma Membrane Modulates the Activation of Hypoxia-inducible Factor 1.

J.Biol.Chem. 277, 23367-23373.

217. Bell, E. L., Emerling, B. M., and Chandel, N. S. (2005). Mitochondrial regulation of oxygen sensing.

Mitochondrion. 5, 322-332.

218. Mansfield, K. D., Guzy, R. D., Pan, Y., Young, R. M., Cash, T. P., Schumacker, P. T., and Simon,

M. C. (2005). Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen

sensing and hypoxic HIF-alpha activation. Cell Metab 1, 393-399.

219. Chandel, N. S., McClintock, D. S., Feliciano, C. E., Wood, T. M., Melendez, J. A., Rodriguez, A. M.,

and Schumacker, P. T. (2000). Reactive Oxygen Species Generated at Mitochondrial Complex III

Stabilize Hypoxia-inducible Factor-1alpha during Hypoxia. A MECHANISM OF O2 SENSING.

J.Biol.Chem. 275, 25130-25138.

220. Sanjuan-Pla, A., Cervera, A. M., Apostolova, N., Garcia-Bou, R., Victor, V. M., Murphy, M. P., and

McCreath, K. J. (2005). A targeted antioxidant reveals the importance of mitochondrial reactive

oxygen species in the hypoxic signaling of HIF-1alpha. FEBS Lett. 579, 2669-2674.

221. Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., and Schumacker, P. T.

(1998). Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad

Sci U S A 95, 11715-11720.

222. Vaux, E. C., Metzen, E., Yeates, K. M., and Ratcliffe, P. J. (2001). Regulation of hypoxia-inducible

factor is preserved in the absence of a functioning mitochondrial respiratory chain. Blood 98, 296-

302.

223. Emerling, B. M., Platanias, L. C., Black, E., Nebreda, A. R., Davis, R. J., and Chandel, N. S. (2005).

Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required

for hypoxia signaling. Mol Cell Biol 25, 4853-4862.

224. Schroedl, C., McClintock, D. S., Budinger, G. R., and Chandel, N. S. (2002). Hypoxic but not anoxic

stabilization of HIF-1alpha requires mitochondrial reactive oxygen species. Am.J Physiol Lung Cell

Mol Physiol 283, L922-L931.

225. To, K. K. and Huang, L. E. (2005). Suppression of HIF-1alpha transcriptional activity by the HIF

prolyl hydroxylase EGLN1. J Biol Chem.

226. Ozer, A., Wu, L. C., and Bruick, R. K. (2005). The candidate tumor suppressor ING4 represses

activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci U S A 102, 7481-7486.


141

227. Maynard, M. A., Evans, A. J., Hosomi, T., Hara, S., Jewett, M. A., and Ohh, M. (2005). Human HIF-

3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma.

FASEB J 19, 1396-1406.

228. Bhattacharya, S., Michels, C. L., Leung, M. K., Arany, Z. P., Kung, A. L., and Livingston, D. M.

(1999). Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1.

Genes Dev. 13, 64-75.

229. Fox, S. B., Braganca, J., Turley, H., Campo, L., Han, C., Gatter, K. C., Bhattacharya, S., and Harris,

A. L. (2004). CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic

location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible

factor 1alpha. Cancer Res 64, 6075-6081.

230. Tacchini, L., Dansi, P., Matteucci, E., and Desiderio, M. A. (2001). Hepatocyte growth factor

signalling stimulates hypoxia inducible factor- 1 (HIF-1) activity in HepG2 hepatoma cells.

Carcinogenesis 22, 1363-1371.

231. Fukuda, R., Hirota, K., Fan, F., Jung, Y. D., Ellis, L. M., and Semenza, G. L. (2002). Insulin-like

growth factor 1 induces hypoxia-inducible factor 1- mediated vascular endothelial growth factor

expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon

cancer cells. J Biol.Chem. 277, 38205-38211.

232. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., Simons, J. W.,

and Semenza, G. L. (2000). Modulation of Hypoxia-inducible Factor 1{{alpha}} Expression by the

Epidermal Growth Factor/Phosphatidylinositol 3-Kinase/PTEN/AKT/FRAP Pathway in Human

Prostate Cancer Cells: Implications for Tumor Angiogenesis and Therapeutics. Cancer Res 60,

1541-1545.

233. Shi, Y. H., Wang, Y. X., You, J. F., Heng, W. J., Zhong, H. H., and Fang, W. G. (2004). [Activation

of HIF-1 by bFGF in breast cancer: role of PI-3K and MEK1/ERK pathways.]. Zhonghua Yi.Xue.Za

Zhi. 84, 1899-1903.

234. Stiehl, D. P., Jelkmann, W., Wenger, R. H., and Hellwig-Burgel, T. (2002). Normoxic induction of the

hypoxia-inducible factor 1[alpha] by insulin and interleukin-1[beta] involves the phosphatidylinositol

3-kinase pathway. FEBS Letters 512, 157-162.

235. Moeller, L. C., Dumitrescu, A. M., and Refetoff, S. (2005). Cytosolic action of thyroid hormone leads

to induction of hypoxia-inducible factor-1alpha and glycolytic genes. Mol Endocrinol 19, 2955-2963.

236. Mabjeesh, N. J., Willard, M. T., Frederickson, C. E., Zhong, H., and Simons, J. W. (2003).

Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase

receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 9,

2416-2425.

237. Zhou, J., Schmid, T., and Brune, B. (2003). Tumor Necrosis Factor-{alpha} Causes Accumulation of

a Ubiquitinated Form of Hypoxia Inducible Factor-1{alpha} through a Nuclear Factor-{kappa}B-

Dependent Pathway. Mol.Biol.Cell 14, 2216-2225.

238. Spinella, F., Rosano, L., Di Castro, V., Natali, P. G., and Bagnato, A. (2002). Endothelin-1 Induces

Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1alpha in Ovarian

Carcinoma Cells. J.Biol.Chem. 277, 27850-27855.

239. Chun, Y. S., Choi, E., Kim, G. T., Lee, M. J., Lee, M. J., Lee, S. E., Kim, M. S., and Park, J. W.

(2000). Zinc induces the accumulation of hypoxia-inducible factor (HIF)-1alpha, but inhibits the

nuclear translocation of HIF-1beta, causing HIF-1 inactivation. Biochem.Biophys.Res Commun.

268, 652-656.


142

240. Lee, S. G., Lee, H., and Rho, H. M. (2001). Transcriptional repression of the human p53 gene by

cobalt chloride mimicking hypoxia. FEBS Lett. 507, 259-263.

241. Gao, N., Ding, M., Zheng, J. Z., Zhang, Z., Leonard, S. S., Liu, K. J., Shi, X., and Jiang, B. H.

(2002). Vanadate-induced Expression of Hypoxia-inducible Factor 1alpha and Vascular Endothelial

Growth Factor through Phosphatidylinositol 3-Kinase/Akt Pathway and Reactive Oxygen Species.

J.Biol.Chem. 277, 31963-31971.

242. Gao, N., Jiang, B. H., Leonard, S. S., Corum, L., Zhang, Z., Roberts, J. R., Antonini, J., Zheng, J. Z.,

Flynn, D. C., Castranova, V., and Shi, X. (2002). p38 Signaling-mediated hypoxia-inducible factor

1alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate

carcinoma cells. J.Biol.Chem. 277, 45041-45048.

243. Sandau, K. B., Zhou, J., Kietzmann, T., and Brune, B. (2001). Regulation of the Hypoxia-inducible

Factor 1alpha by the Inflammatory Mediators Nitric Oxide and Tumor Necrosis Factor-alpha in

Contrast to Desferroxamine and Phenylarsine Oxide. J.Biol.Chem. 276, 39805-39811.

244. Chong, T. W., Horwitz, L. D., Moore, J. W., Sowter, H. M., and Harris, A. L. (2002). A mycobacterial

iron chelator, desferri-exochelin, induces hypoxia- inducible factors 1 and 2, NIP3, and vascular

endothelial growth factor in cancer cell lines. Cancer Res 62, 6924-6927.

245. Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J. Activation of the HIF pathway in cancer. Current

Opinion in Genetics and Development 11, 293-299. 2001.

Ref Type: Generic

246. Wakisaka, N., Kondo, S., Yoshizaki, T., Murono, S., Furukawa, M., and Pagano, J. S. (2004).

Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha.

Mol Cell Biol 24, 5223-5234.

247. Sanchez-Elsner, T., Botella, L. M., Velasco, B., Corbi, A., Attisano, L., and Bernabeu, C. (2001).

Synergistic Cooperation between Hypoxia and Transforming Growth Factor-beta Pathways on

Human Vascular Endothelial Growth Factor Gene Expression. J.Biol.Chem. 276, 38527-38535.

248. Zhang, S. X. L., Gozal, D., Sachleben, J., Rane, M., Klein, J. B., and Gozal, E. (2003). Hypoxia

induces an autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-B/PDGF-

β receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A neuronal cells. FASEB J. 02-

1111fje.

249. Tacchini, L., Matteucci, E., De Ponti, C., and Desiderio, M. A. (2003). Hepatocyte growth factor

signaling regulates transactivation of genes belonging to the plasminogen activation system via

hypoxia inducible factor-1. Exp Cell Res 290, 391-401.

250. Zhu, G., Saed, G. M., Deppe, G., Diamond, M. P., and Munkarah, A. R. (2004). Hypoxia up-

regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells.

Gynecol.Oncol 94, 422-426.

251. Lison, D., De Boeck, M., Verougstraete, V., and Kirsch-Volders, M. (2001). Update on the

genotoxicity and carcinogenicity of cobalt compounds. Occup.Environ.Med 58, 619-625.

252. Williams, D. R. (1972). Metals, ligands, and cancer. Chem.Rev 72, 203-213.

253. Salnikow, K., Donald, S. P., Bruick, R. K., Zhitkovich, A., Phang, J. M., and Kasprzak, K. S. (2004).

Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the

induction of hypoxic stress. J Biol Chem. 279, 40337-40344.

254. Hirsila, M., Koivunen, P., Xu, L., Seeley, T., Kivirikko, K. I., and Myllyharju, J. (2005). Effect of

desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J 19,

1308-1310.


143

255. Yuan, Y., Beitner-Johnson, D., and Millhorn, D. E. (2001). Hypoxia-inducible factor 2alpha binds to

cobalt in vitro. Biochem.Biophys.Res Commun. 288, 849-854.

256. Yuan, Y., Hilliard, G., Ferguson, T., and Millhorn, D. E. (2003). Cobalt Inhibits the Interaction

between Hypoxia-inducible Factor-alpha and von Hippel-Lindau Protein by Direct Binding to

Hypoxia-inducible Factor-alpha. J.Biol.Chem. 278, 15911.

257. Kanaya, K., Tsai, A. L., and Kamitani, T. (2002). Cobalt- and nickel-binding property of cullin-2.

Biochem.Biophys.Res Commun. 290, 294-299.

258. Chachami, G., Simos, G., Hatziefthimiou, A., Bonanou, S., Molyvdas, P. A., and Paraskeva, E.

(2004). Cobalt induces hypoxia-inducible factor-1alpha expression in airway smooth muscle cells by

a reactive oxygen species- and PI3K-dependent mechanism. Am J Respir.Cell Mol Biol 31, 544-

551.

259. Peters, K., Schmidt, H., Unger, R. E., Kamp, G., Prols, F., Berger, B. J., and Kirkpatrick, C. J.

(2005). Paradoxical effects of hypoxia-mimicking divalent cobalt ions in human endothelial cells in

vitro. Mol Cell Biochem 270, 157-166.

260. Sandau, K. B., Fandrey, J., and Brune, B. (2001). Accumulation of HIF-1alpha under the influence

of nitric oxide. Blood 97, 1009-1015.

261. Kasuno, K., Takabuchi, S., Fukuda, K., Kizaka-Kondoh, S., Yodoi, J., Adachi, T., Semenza, G. L.,

and Hirota, K. (2004). Nitric Oxide Induces Hypoxia-inducible Factor 1 Activation That Is Dependent

on MAPK and Phosphatidylinositol 3-Kinase Signaling. J.Biol.Chem. 279, 2550-2558.

262. Yasinska, I. M. and Sumbayev, V. V. (2003). S-nitrosation of Cys-800 of HIF-1[alpha] protein

activates its interaction with p300 and stimulates its transcriptional activity. FEBS Letters 549, 105-

109.

263. Zhang, Z., Ren, J., Harlos, K., McKinnon, C. H., Clifton, I. J., and Schofield, C. J. (2002). Crystal

structure of a clavaminate synthase-Fe(II)-2-oxoglutarate-substrate-NO complex: evidence for metal

centered rearrangements. FEBS Lett. 517, 7-12.

264. Zhong, H., Mabjeesh, N., Willard, M., and Simons, J. (2002). Nuclear expression of hypoxia-

inducible factor 1alpha protein is heterogeneous in human malignant cells under normoxic

conditions. Cancer Lett. 181, 233-238.

265. Anastasiadis, A. G., Ghafar, M. A., Salomon, L., Vacherot, F., Benedit, P., Chen, M. W., Shabsigh,

A., Burchardt, M., Chopin, D. K., Shabsigh, R., and Buttyan, R. (2002). Human hormone-refractory

prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia

inducible factor-1alpha (HIF-1alpha). J Cancer Res Clin Oncol 128, 358-362.

266. Chau, C. H., Permenter, M. G., Steinberg, S. M., Retter, A. S., Dahut, W. L., Price, D. K., and Figg,

W. D. (2005). Polymorphism in the Hypoxia-Inducible Factor 1alpha Gene May Confer Susceptibility

to Androgen-Independent Prostate Cancer. Cancer Biol Ther 4.

267. Tanimoto, K., Yoshiga, K., Eguchi, H., Kaneyasu, M., Ukon, K., Kumazaki, T., Oue, N., Yasui, W.,

Imai, K., Nakachi, K., Poellinger, L., and Nishiyama, M. (2003). Hypoxia-inducible factor-1alpha

polymorphisms associated with enhanced transactivation capacity, implying clinical significance.

Carcinogenesis 24, 1779-1783.

268. Ollerenshaw, M., Page, T., Hammonds, J., and Demaine, A. (2004). Polymorphisms in the hypoxia

inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype.

Cancer Genet Cytogenet. 153, 122-126.

269. Kuwai, T., Kitadai, Y., Tanaka, S., Kuroda, T., Ochiumi, T., Matsumura, S., Oue, N., Yasui, W.,

Kaneyasu, M., Tanimoto, K., Nishiyama, M., and Chayama, K. (2004). Single nucleotide


144

polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma. Oncol Rep. 12,

1033-1037.

270. Fu, X. S., Choi, E., Bubley, G. J., and Balk, S. P. (2005). Identification of hypoxia-inducible factor-

1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced

degradation. Prostate 63, 215-221.

271. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., and Kaelin, W. G., Jr. (2002). Inhibition of HIF

is necessary for tumor suppression by the von Hippel- Lindau protein. Cancer Cell 1, 237-246.

272. Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., and Klausner, R. D.

(2002). The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in

renal cell carcinoma. Cancer Cell 1, 247-255.

273. Miller, F., Kentsis, A., Osman, R., and Pan, Z. Q. (2005). Inactivation of VHL by Tumorigenic

Mutations That Disrupt Dynamic Coupling of the pVHL{middle dot}Hypoxia-inducible Transcription

Factor-1{alpha} Complex. J.Biol.Chem. 280, 7985-7996.

274. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L.,

McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M.

H., and Parsons, R. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human

brain, breast, and prostate cancer. Science 275, 1943-1947.

275. Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan,

H. E., Johnson, R. S., Jefferson, A. B., Stokoe, D., and Giaccia, A. J. (2000). Loss of PTEN

facilitates HIF-1-mediated gene expression. Genes Dev. 14, 391-396.

276. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. (1991). p53 mutations in human

cancers. Science 253, 49-53.

277. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. (1997). Regulation of p53 stability by Mdm2.

Nature 387, 299-303.

278. Fatyol, K. and Szalay, A. A. (2001). The p14ARF Tumor Suppressor Protein Facilitates Nucleolar

Sequestration of Hypoxia-inducible Factor-1alpha (HIF-1alpha ) and Inhibits HIF-1-mediated

Transcription. J.Biol.Chem. 276, 28421-28429.

279. Chan, D. A., Sutphin, P. D., Denko, N. C., and Giaccia, A. J. (2002). Role of prolyl hydroxylation in

oncogenically stabilized hypoxia- inducible factor-1alpha. J.Biol.Chem. 277, 40112-40117.

280. Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. (1997). Induction of vascular

endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling

pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element.

Blood 90, 3322-3331.

281. Racker, E., Resnick, R. J., and Feldman, R. (1985). Glycolysis and methylaminoisobutyrate uptake

in rat-1 cells transfected with ras or myc oncogenes. Proc Natl Acad Sci U S A 82, 3535-3538.

282. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. (1995).

Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of

tumor angiogenesis. Cancer Res 55, 4575-4580.

283. Blancher, C., Moore, J. W., Robertson, N., and Harris, A. L. (2001). Effects of ras and von Hippel-

Lindau (VHL) Gene Mutations on Hypoxia-inducible Factor (HIF)-1{alpha}, HIF-2{alpha}, and

Vascular Endothelial Growth Factor Expression and Their Regulation by the Phosphatidylinositol 3'-

Kinase/Akt Signaling Pathway. Cancer Res 61, 7349-7355.

284. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J.,

Waterfield, M. D., and Downward, J. (1994). Phosphatidylinositol-3-OH kinase as a direct target of

Ras. Nature 370, 527-532.


145

285. Pouyssegur, J., Volmat, V., and Lenormand, P. (2002). Fidelity and spatio-temporal control in MAP

kinase (ERKs) signalling. Biochem Pharmacol 64, 755-763.

286. Karni, R., Dor, Y., Keshet, E., Meyuhas, O., and Levitzki, A. (2002). Activated pp60c-Src leads to

elevated hypoxia-inducible factor (HIF)- 1alpha expression under normoxia. J Biol.Chem. 277,

42919-42925.

287. Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M.,

Bono, F., Abramovitch, R., Maxwell, P., Koch, C. J., Ratcliffe, P., Moons, L., Jain, R. K., Collen, D.,

Keshert, E., and Keshet, E. (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell

proliferation and tumour angiogenesis. Nature 394, 485-490.

288. Uchida, T., Rossignol, F., Matthay, M. A., Mounier, R., Couette, S., Clottes, E., and Clerici, C.

(2004). Prolonged Hypoxia Differentially Regulates Hypoxia-inducible Factor (HIF)-1{alpha} and

HIF-2{alpha} Expression in Lung Epithelial Cells: IMPLICATION OF NATURAL ANTISENSE HIF-

1{alpha}. J.Biol.Chem. 279, 14871-14878.

289. Demidenko, Z. N., Rapisarda, A., Garayoa, M., Giannakakou, P., Melillo, G., and Blagosklonny, M.

V. (2005). Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent

depletion. Oncogene 24, 4829-4838.

290. Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B., and Simon, M. C. (2003). Differential roles of

hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell

Biol 23, 9361-9374.

291. Bracken, C. P., Whitelaw, M. L., and Peet, D. J. (2005). Activity of Hypoxia-inducible Factor 2{alpha}

Is Regulated by Association with the NF-{kappa}B Essential Modulator. J.Biol.Chem. 280, 14240-

14251.

292. Wiesener, M. S., Jurgensen, J. S., Rosenberger, C., Scholze, C. K., Horstrup, J. H., Warnecke, C.,

Mandriota, S., Bechmann, I., Frei, U. A., Pugh, C. W., Ratcliffe, P. J., Bachmann, S., Maxwell, P. H.,

and Eckardt, K. U. (2003). Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell

populations of different organs. FASEB J 17, 271-273.

293. Wiesener, M. S., Turley, H., Allen, W. E., Willam, C., Eckardt, K. U., Talks, K. L., Wood, S. M.,

Gatter, K. C., Harris, A. L., Pugh, C. W., Ratcliffe, P. J., and Maxwell, P. H. (1998). Induction of

endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-

inducible factor-1alpha. Blood 92, 2260-2268.

294. Holmquist, L., Jogi, A., and Pahlman, S. (2005). Phenotypic persistence after reoxygenation of

hypoxic neuroblastoma cells. Int J Cancer 116, 218-225.

295. Wang, V., Davis, D. A., Haque, M., Huang, L. E., and Yarchoan, R. (2005). Differential Gene Up-

Regulation by Hypoxia-Inducible Factor-1{alpha} and Hypoxia-Inducible Factor-2{alpha} in

HEK293T Cells. Cancer Res 65, 3299-3306.

296. Brusselmans, K., Bono, F., Maxwell, P., Dor, Y., Dewerchin, M., Collen, D., Herbert, J. M., and

Carmeliet, P. (2001). Hypoxia-inducible Factor-2alpha (HIF-2alpha ) Is Involved in the Apoptotic

Response to Hypoglycemia but Not to Hypoxia. J.Biol.Chem. 276, 39192-39196.

297. Bertges, D. J., Berg, S., Fink, M. P., and Delude, R. L. (2002). Regulation of hypoxia-inducible

factor 1 in enterocytic cells. J.Surg.Res 106, 157-165.

298. Belanger, A. J., Lu, H., Date, T., Liu, L. X., Vincent, K. A., Akita, G. Y., Cheng, S. H., Gregory, R. J.,

and Jiang, C. (2002). Hypoxia up-regulates expression of peroxisome proliferator-activated receptor

gamma angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor

1alpha. J.Mol Cell Cardiol. 34 , 765-774.


146

299. Jung, F., Haendeler, J., Hoffmann, J., Reissner, A., Dernbach, E., Zeiher, A. M., and Dimmeler, S.

(2002). Hypoxic Induction of the Hypoxia-Inducible Factor Is Mediated via the Adaptor Protein Shc

in Endothelial Cells. Circ Res 91, 38.

300. BelAiba, R. S., Djordjevic, T., Bonello, S., Flugel, D., Hess, J., Kietzmann, T., and Gorlach, A.

(2004). Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary

artery smooth muscle cells. Biol Chem. 385, 249-257.

301. Wang, Y. Q., Luk, J. M., Ikeda, K., Man, K., Chu, A. C., Kaneda, K., and Tat Fan, S. (2004).

Regulatory role of vHL/HIF-1[alpha] in hypoxia-induced VEGF production in hepatic stellate cells.

Biochemical and Biophysical Research Communications 317, 358-362.

302. Karhausen, J., Haase, V. H., and Colgan, S. P. (2005). Inflammatory hypoxia: role of hypoxia-

inducible factor. Cell Cycle 4, 256-258.

303. Scortegagna, M., Morris, M. A., Oktay, Y., Bennett, M., and Garcia, J. A. (2003). The HIF family

member EPAS1/HIF-2{alpha} is required for normal hematopoiesis in mice. Blood 102, 1634-1640.

304. Licht, A. H., Muller-Holtkamp, F., Flamme, I., and Breier, G. (2005). Inhibition of hypoxia-inducible

factor activity in endothelial cells disrupts embryonic cardiovascular development. Blood.

305. Freeburg, P. B., Robert, B., St John, P. L., and Abrahamson, D. R. (2003). Podocyte expression of

hypoxia-inducible factor (HIF)-1 and HIF-2 during glomerular development. J Am Soc.Nephrol. 14,

927-938.

306. Wagner, K. F., Hellberg, A. K., Balenger, S., Depping, R., Dodd, O., Johns, R. A., and Li, D. (2004).

Hypoxia-induced mitogenic factor has antiapoptotic action and is upregulated in the developing

lung: coexpression with hypoxia-inducible factor-2alpha. Am J Respir.Cell Mol Biol 31, 276-282.

307. Scortegagna, M., Ding, K., Zhang, Q., Oktay, Y., Bennett, M. J., Bennett, M., Shelton, J. M.,

Richardson, J. A., Moe, O., and Garcia, J. A. (2005). HIF-2alpha regulates murine hematopoietic

development in an erythropoietin-dependent manner. Blood 105, 3133-3140.

308. Duan, L. J., Zhang-Benoit, Y., and Fong, G. H. (2005). Endothelium-intrinsic requirement for Hif-

2alpha during vascular development. Circulation 111, 2227-2232.

309. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs,

W. B., Semenza, G. L., and Simons, J. W. (1999). Overexpression of hypoxia-inducible factor

1alpha in common human cancers and their metastases. Cancer Res 59, 5830-5835.

310. Birner, P., Schindl, M., Obermair, A., Breitenecker, G., and Oberhuber, G. (2001). Expression of

hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on

response to chemotherapy. Clin.Cancer Res 7, 1661-1668.

311. Theodoropoulos, V. E., Lazaris, A. C., Sofras, F., Gerzelis, I., Tsoukala, V., Ghikonti, I., Manikas, K.,

and Kastriotis, I. (2004). Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis

and unfavorable prognosis in bladder cancer. Eur Urol. 46, 200-208.

312. Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., Iyer, N., LaRusch,

J., Pak, B., Taghavi, P., and Semenza, G. L. (2003). Regulation of Colon Carcinoma Cell Invasion

by Hypoxia-Inducible Factor 1. Cancer Res 63, 1138.

313. Jogi, A., Vallon-Christersson, J., Holmquist, L., Axelson, H., Borg, A., and Pahlman, S. (2004).

Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth,

survival, and aggressive behavior. Experimental Cell Research 295, 469-487.

314. Kimura, S., Kitadai, Y., Tanaka, S., Kuwai, T., Hihara, J., Yoshida, K., Toge, T., and Chayama, K.

(2004). Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial

growth factor expression and tumour angiogenesis in human oesophageal squamous cell

carcinoma. Eur J Cancer 40, 1904-1912.


147

315. Buchler, P., Reber, H. A., Lavey, R. S., Tomlinson, J., Buchler, M. W., Friess, H., and Hines, O. J.

(2004). Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic

murine model. J Surg.Res 120, 295-303.

316. Beasley, N. J., Leek, R., Alam, M., Turley, H., Cox, G. J., Gatter, K., Millard, P., Fuggle, S., and

Harris, A. L. (2002). Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer:

relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62,

2493-2497.

317. Onita, T., Ji, P. G., Xuan, J. W., Sakai, H., Kanetake, H., Maxwell, P. H., Fong, G. H., Gabril, M. Y.,

Moussa, M., and Chin, J. L. (2002). Hypoxia-induced, perinecrotic expression of endothelial Per-

ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression,

vascularization, and focal macrophage infiltration in bladder cancer. Clin.Cancer Res 8, 471-480.

318. Piret, J. P., Lecocq, C., Toffoli, S., Ninane, N., Raes, M., and Michiels, C. (2004). Hypoxia and

CoCl2 protect HepG2 cells against serum deprivation- and t-BHP-induced apoptosis: a possible

anti-apoptotic role for HIF-1. Experimental Cell Research 295, 340-349.

319. Weinmann, M., Jendrossek, V., Handrick, R., Guner, D., Goecke, B., and Belka, C. (2004).

Molecular ordering of hypoxia-induced apoptosis: critical involvement of the mitochondrial death

pathway in a FADD/caspase-8 independent manner. Oncogene 23, 3757-3769.

320. Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H. P., Johnson, R. S., and Bergers,

G. (2003). The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4,

133-146.

321. Teicher, B. A. (1994). Hypoxia and drug resistance. Cancer Metastasis Rev 13, 139-168.

322. Moeller, B. J., Cao, Y., Li, C. Y., and Dewhirst, M. W. (2004). Radiation activates HIF-1 to regulate

vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer

Cell 5, 429-441.

323. Xia, S., Yu, S. Y., Yuan, X. L., and Xu, S. P. (2004). Effects of hypoxia on expression of P-

glycoprotein and mutltidrug resistance protein in human lung adenocarcinoma A549 cell line.

Zhonghua Yi.Xue.Za Zhi. 84, 663-666.

324. Erler, J. T., Cawthorne, C. J., Williams, K. J., Koritzinsky, M., Wouters, B. G., Wilson, C., Miller, C.,

Demonacos, C., Stratford, I. J., and Dive, C. (2004). Hypoxia-mediated down-regulation of Bid and

Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and

contributes to drug resistance. Mol Cell Biol 24, 2875-2889.

325. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., and Dewhirst, M. W. (1997). Tumor hypoxia

adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat.Oncol Biol Phys.

38, 285-289.

326. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Simopoulos, C., Turley, H., Talks, K., Gatter, K.

C., and Harris, A. L. (2002). Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and

chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int.J.Radiat.Oncol.Biol.Phys.

53, 1192-1202.

327. Brown, L. M., Cowen, R. L., Debray, C., Eustace, A., Erler, J. T., Sheppard, F. C., Parker, C. A.,

Stratford, I. J., and Williams, K. J. (2005). REVERSING HYPOXIC CELL CHEMORESISTANCE IN

VITRO USING GENETIC AND SMALL MOLECULE APPROACHES TARGETING HYPOXIA

INDUCIBLE FACTOR-1. Mol Pharmacol.

328. Rak, J. and Yu, J. L. (2004). Oncogenes and tumor angiogenesis: The question of vascular 'supply'

and vascular 'demand'. Seminars in Cancer Biology 14, 93-104.


148

329. Kaanders, J. H., Pop, L. A., Marres, H. A., Bruaset, I., van den Hoogen, F. J., Merkx, M. A., and van

der Kogel, A. J. (2002). ARCON: experience in 215 patients with advanced head-and-neck cancer.

Int J Radiat.Oncol Biol Phys. 52, 769-778.

330. Brown, J. M. and Wilson, W. R. (2004). Exploiting tumour hypoxia in cancer treatment.

Nat.Rev.Cancer 4, 437-447.

331. Brown, J. M. and Lemmon, M. J. (1990). Potentiation by the hypoxic cytotoxin SR 4233 of cell killing

produced by fractionated irradiation of mouse tumors. Cancer Res 50 , 7745-7749.

332. Lunt, S. J., Telfer, B. A., Fitzmaurice, R. J., Stratford, I. J., and Williams, K. J. (2005). Tirapazamine

administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. Clin Cancer Res

11, 4212-4216.

333. Rischin, D., Peters, L., Hicks, R., Hughes, P., Fisher, R., Hart, R., Sexton, M., D'Costa, I., and von

Roemeling, R. (2001). Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in

patients with advanced head and neck cancer. J Clin Oncol 19, 535-542.

334. Dorie, M. J. and Brown, J. M. (1993). Tumor-specific, schedule-dependent interaction between

tirapazamine (SR 4233) and cisplatin. Cancer Res 53, 4633-4636.

335. Rischin, D., Peters, L., Fisher, R., Macann, A., Denham, J., Poulsen, M., Jackson, M., Kenny, L.,

Penniment, M., Corry, J., Lamb, D., and McClure, B. (2005). Tirapazamine, Cisplatin, and Radiation

versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck

cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).

J Clin Oncol 23, 79-87.

336. Patterson, L. H. (2002). Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique

approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev 34, 581-592.

337. Gallagher, R., Hughes, C. M., Murray, M. M., Friery, O. P., Patterson, L. H., Hirst, D. G., and

McKeown, S. R. (2001). The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.

Br J Cancer 85, 625-629.

338. Loadman, P. M., Swaine, D. J., Bibby, M. C., Welham, K. J., and Patterson, L. H. (2001). A

preclinical pharmacokinetic study of the bioreductive drug AQ4N. Drug Metab Dispos. 29, 422-426.

339. Wilson, W. R., Tercel, M., Anderson, R. F., and Denny, W. A. (1998). Radiation-activated prodrugs

as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts. Anticancer

Drug Des 13, 663-685.

340. Dai, S., Huang, M. L., Hsu, C. Y., and Chao, K. S. C. (2003). Inhibition of hypoxia inducible factor

1[alpha] causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in

glioblastoma cells. International Journal of Radiation Oncology*Biology*Physics 55, 1027-1036.

341. Sun, X. Y., Meng, F. Q., Jiang, H. C., Qiao, H. Q., and Li, W. (2005). [Antisense hypoxia inducible

factor-1alpha and B7-1 combination gene therapy for mouse lymphoma.]. Zhonghua Zhong.Liu Za

Zhi. 27, 404-407.

342. Mizuno, T., Nagao, M., Yamada, Y., Narikiyo, M., Ueno, M., Miyagishi, M., Taira, K., and Nakajima,

Y. (2005). Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha

inhibits tumor growth in hepatobiliary and pancreatic cancers. Cancer Gene Ther .

343. Harada, H., Hiraoka, M., and Kizaka-Kondoh, S. (2002). Antitumor effect of TAT-oxygen-dependent

degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.

Cancer Res 62, 2013-2018.

344. Wang, D., Ruan, H., Hu, L., Lamborn, K. R., Kong, E. L., Rehemtulla, A., and Deen, D. F. (2005).

Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed

prodrug cancer therapy. Cancer Gene Ther 12, 276-283.


149

345. Post, D. E. and Van Meir, E. G. (2003). A novel hypoxia-inducible factor (HIF) activated oncolytic

adenovirus for cancer therapy. Oncogene 22, 2065-2072.

346. Pipiya, T., Sauthoff, H., Huang, Y. Q., Chang, B., Cheng, J., Heitner, S., Chen, S., Rom, W. N., and

Hay, J. G. (2005). Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral

protein expression. Gene Ther 12, 911-917.

347. Shen, B. H. and Hermiston, T. W. (2005). Effect of hypoxia on Ad5 infection, transgene expression

and replication. Gene Ther 12, 902-910.

348. Pin, R. H., Reinblatt, M., Bowers, W. J., Federoff, H. J., and Fong, Y. (2004). Herpes simplex virus

amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in

hepatocellular carcinoma. J Gastrointest.Surg. 8, 812-822.

349. Fox, M. E., Lemmon, M. J., Mauchline, M. L., Davis, T. O., Giaccia, A. J., Minton, N. P., and Brown,

J. M. (1996). Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of

5-fluorocytosine by genetically engineered clostridia. Gene Ther 3, 173-178.

350. Yazawa, K., Fujimori, M., Nakamura, T., Sasaki, T., Amano, J., Kano, Y., and Taniguchi, S. (2001).

Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary

tumors. Breast Cancer Res Treat. 66, 165-170.

351. Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., and Melillo, G. (2004).

Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1: Mechanism and Therapeutic

Implications. Cancer Res 64, 1475-1482.

352. Lund, E. L., Hansen, L. T., and Kristjansen, P. E. (2005). Augmenting tumor sensitivity to topotecan

by transient hypoxia. Cancer Chemother.Pharmacol.

353. Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., and Powis, G. (2004). Antitumor activity

and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol

Cancer Ther 3, 233-244.

354. Jones, M. K., Szabo, I. L., Kawanaka, H., Husain, S. S., and Tarnawski, A. S. (2002). von Hippel

Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced

angiogenesis. FASEB J. 16, 264-266.

355. Mabjeesh, N. J., Post, D. E., Willard, M. T., Kaur, B., Van Meir, E. G., Simons, J. W., and Zhong, H.

(2002). Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the

proteosome pathway in prostate cancer cells. Cancer Res 62, 2478-2482.

356. Ibrahim, N. O., Hahn, T., Franke, C., Stiehl, D. P., Wirthner, R., Wenger, R. H., and Katschinski, D.

M. (2005). Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90

inhibitors. Cancer Res 65, 11094-11100.

357. Erez, N., Milyavsky, M., Eilam, R., Shats, I., Goldfinger, N., and Rotter, V. (2003). Expression of

prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and

inhibits tumor growth. Cancer Res 63, 8777-8783.

358. D'Angelo, G., Duplan, E., Vigne, P., and Frelin, C. (2003). Cyclosporin A prevents the hypoxic

adaptation by activating hypoxia-inducible factor-1alpha Pro-564 hydroxylation. J Biol Chem. 278,

15406-15411.

359. Temes, E., Martin-Puig, S., Acosta-Iborra, B., Castellanos, M. C., Feijoo-Cuaresma, M., Olmos, G.,

Aragones, J., and Landazuri, M. O. (2005). Activation of HIF-prolyl hydroxylases by R59949, an

inhibitor of the diacylglycerol kinase. J Biol Chem. 280, 24238-24244.

360. Mie, L. Y., Kim, S. H., Kim, H. S., Jin, S. M., Nakajima, H., Jeong, K. H., and Kim, K. W. (2003).

Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via

suppression of HIF-1alpha activity. Biochem Biophys.Res Commun. 300, 241-246.


150

361. Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J. E., Lee, S. W., Moon, E. J., Kim, H. S.,

Lee, S. K., Chung, H. Y., Kim, C. W., and Kim, K. W. (2001). Histone deacetylases induce

angiogenesis by negative regulation of tumor suppressor genes. Nat.Med. 7, 437-443.

362. Welsh, S. J., Williams, R. R., Birmingham, A., Newman, D. J., Kirkpatrick, D. L., and Powis, G.

(2003). The Thioredoxin Redox Inhibitors 1-Methylpropyl 2-Imidazolyl Disulfide and Pleurotin Inhibit

Hypoxia-induced Factor 1{alpha} and Vascular Endothelial Growth Factor Formation. Mol Cancer

Ther 2, 235.

363. Petit, A. M., Rak, J., Hung, M. C., Rockwell, P., Goldstein, N., Fendly, B., and Kerbel, R. S. (1997).

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases

down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo:

angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151, 1523-

1530.

364. Chang, H., Shyu, K. G., Lee, C. C., Tsai, S. C., Wang, B. W., Hsien, L. Y., and Lin, S. (2003).

GL331 inhibits HIF-1alpha expression in a lung cancer model. Biochem Biophys.Res Commun.

302, 95-100.

365. Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard,

M. T., Zhong, H., Simons, J. W., and Giannakakou, P. (2003). 2ME2 inhibits tumor growth and

angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363-375.

366. Ricker, J. L., Chen, Z., Yang, X. P., Pribluda, V. S., Swartz, G. M., and Van Waes, C. (2004). 2-

methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and

augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 10,

8665-8673.

367. Cao, Z., Fang, J., Xia, C., Shi, X., and Jiang, B. H. (2004). trans-3,4,5'-Trihydroxystibene inhibits

hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian

cancer cells. Clin Cancer Res 10, 5253-5263.

368. Yeo, E. J., Chun, Y. S., Cho, Y. S., Kim, J., Lee, J. C., Kim, M. S., and Park, J. W. (2003). YC-1: A

Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1. JNCI Cancer Spectrum 95, 516-

525.

369. Luwor, R. B., Lu, Y., Li, X., Mendelsohn, J., and Fan, Z. (2005). The antiepidermal growth factor

receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to

transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24, 4433-4441.

370. Li, L., Lin, X., Staver, M., Shoemaker, A., Semizarov, D., Fesik, S. W., and Shen, Y. (2005).

Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA

interference in vivo. Cancer Res 65, 7249-7258.

371. Yoshimura, H., Dhar, D. K., Kohno, H., Kubota, H., Fujii, T., Ueda, S., Kinugasa, S., Tachibana, M.,

and Nagasue, N. (2004). Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in

colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression.

Clin Cancer Res 10, 8554-8560.

372. Covello, K. L., Simon, M. C., and Keith, B. (2005). Targeted Replacement of Hypoxia-Inducible

Factor-1{alpha} by a Hypoxia-Inducible Factor-2{alpha} Knock-in Allele Promotes Tumor Growth.

Cancer Res 65, 2277-2286.

373. Acker, T., Diez-Juan, A., Aragones, J., Tjwa, M., Brusselmans, K., Moons, L., Fukumura, D.,

Moreno-Murciano, M. P., Herbert, J. M., Burger, A., Riedel, J., Elvert, G., Flamme, I., Maxwell, P.

H., Collen, D., Dewerchin, M., Jain, R. K., Plate, K. H., and Carmeliet, P. (2005). Genetic evidence

for a tumor suppressor role of HIF-2alpha. Cancer Cell 8, 131-141.


151

374. Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., and Kerbel, R. S. (2002). Effect of p53 status on

tumor response to antiangiogenic therapy. Science 295, 1526-1528.

375. Allen, C. B., Schneider, B. K., and White, C. W. (2001). Limitations to oxygen diffusion and

equilibration in in vitro cell exposure systems in hyperoxia and hypoxia. Am.J.Physiol Lung Cell Mol

Physiol 281, L1021-L1027.

376. Kotelevets, L., van Hengel, J., Bruyneel, E., Mareel, M., van Roy, F., and Chastre, E. (2001). The

lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting

invasiveness. J.Cell Biol. 155, 1129-1136.

377. Subramanian, A. and Miller, D. M. (2000). Structural analysis of alpha-enolase. Mapping the

functional domains involved in down-regulation of the c-myc protooncogene. J Biol Chem. 275,

5958-5965.

378. Sasaki, Y., Ohsawa, K., Kanazawa, H., Kohsaka, S., and Imai, Y. (2001). Iba1 is an actin-cross-

linking protein in macrophages/microglia. Biochem Biophys.Res Commun. 286 , 292-297.

379. Mottet, D., Michel, G., Renard, P., Ninane, N., Raes, M., and Michiels, C. (2002). ERK and calcium

in activation of HIF-1. Ann.N.Y.Acad.Sci. 973, 448-453.

380. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., and Comoglio, P. M.

(2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.

Cancer Cell 3, 347-361.

381. Hayano, T. and Kikuchi, M. (1995). Cloning and sequencing of the cDNA encoding human P5.

Gene 164, 377-378.

382. Tanaka, S., Uehara, T., and Nomura, Y. (2000). Up-regulation of Protein-disulfide Isomerase in

Response to Hypoxia/Brain Ischemia and Its Protective Effect against Apoptotic Cell Death.

J.Biol.Chem. 275, 10388-10393.

383. Sakai, J., Ishikawa, H., Kojima, S., Satoh, H., Yamamoto, S., and Kanaoka, M. (2003). Proteomic

analysis of rat heart in ischemia and ischemia-reperfusion using fluorescence two-dimensional

difference gel electrophoresis. Proteomics 3, 1318-1324.

384. Sullivan, D. C., Huminiecki, L., Moore, J. W., Boyle, J. J., Poulsom, R., Creamer, D., Barker, J., and

Bicknell, R. (2003). EndoPDI, a Novel Protein-disulfide Isomerase-like Protein That Is Preferentially

Expressed in Endothelial Cells Acts as a Stress Survival Factor. J.Biol.Chem. 278, 47079-47088.

385. Kivirikko, K. I. and Myllyharju, J. (1998). Prolyl 4-hydroxylases and their protein disulfide isomerase

subunit. Matrix Biol. 16, 357-368.

386. Lee, K. A., Shim, J. H., Kho, C. W., Park, S. G., Park, B. C., Kim, J. W., Lim, J. S., Choe, Y. K.,

Paik, S. G., and Yoon, D. Y. (2004). Protein profiling and identification of modulators regulated by

the E7 oncogene in the C33A cell line by proteomics and genomics. Proteomics 4, 839-848.

387. Ryu, J. W., Kim, H. J., Lee, Y. S., Myong, N. H., Hwang, C. H., Lee, G. S., and Yom, H. C. (2003).

The proteomics approach to find biomarkers in gastric cancer. J Korean Med Sci 18, 505-509.

388. Chahed, K., Kabbage, M., Ehret-Sabatier, L., Lemaitre-Guillier, C., Remadi, S., Hoebeke, J., and

Chouchane, L. (2005). Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the

human infiltrating ductal carcinoma of the breast: the two-dimensional electrophoresis and MALDI-

TOF-mass spectrometry analyses. Int J Oncol 27, 1425-1431.

389. Shen, J., Person, M. D., Zhu, J., Abbruzzese, J. L., and Li, D. (2004). Protein expression profiles in

pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by

pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer

Res 64, 9018-9026.


152

390. Stierum, R., Gaspari, M., Dommels, Y., Ouatas, T., Pluk, H., Jespersen, S., Vogels, J., Verhoeckx,

K., Groten, J., and Ommen, B. v. (2003). Proteome analysis reveals novel proteins associated with

proliferation and differentiation of the colorectal cancer cell line Caco-2. Biochimica et Biophysica

Acta (BBA) - Proteins & Proteomics 1650, 73-91.

391. Siddiq, A., Ayoub, I. A., Chavez, J. C., Aminova, L., Shah, S., LaManna, J. C., Patton, S. M.,

Connor, J. R., Cherny, R. A., Volitakis, I., Bush, A., Langsetmo, I., Seeley, T., Gunzler, V., and

Ratan, R. R. (2005). HIF prolyl 4-hydroxylase inhibition: A target for neuroprotection in the central

nervous system. J Biol Chem.

392. Ghosh, A. K., Steele, R., and Ray, R. B. (2005). c-myc Promoter-binding protein 1 (MBP-1)

regulates prostate cancer cell growth by inhibiting MAPK pathway. J Biol Chem. 280, 14325-14330.

393. Fan, X., Solomon, H., Schwarz, K., Kew, M. C., Ray, R. B., and Di Bisceglie, A. M. (2001).

Expression of c-myc promoter binding protein (MBP-1), a novel eukaryotic repressor gene, in

cirrhosis and human hepatocellular carcinoma. Dig.Dis.Sci 46, 563-566.

394. Gerbitz, K. D., Summer, J., Schumacher, I., Arnold, H., Kraft, A., and Mross, K. (1986). Enolase

isoenzymes as tumour markers. J Clin Chem.Clin Biochem 24, 1009-1016.

395. Chang, Y. S., Wu, W., Walsh, G., Hong, W. K., and Mao, L. (2003). Enolase-alpha is frequently

down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin

Cancer Res 9, 3641-3644.

396. Wolf, D. H. and Hilt, W. (2004). The proteasome: a proteolytic nanomachine of cell regulation and

waste disposal. Biochim.Biophys.Acta 1695, 19-31.

397. Brahimi-Horn, C. and Pouyssegur, J. (2005). When hypoxia signalling meets the ubiquitin-

proteasomal pathway, new targets for cancer therapy. Critical Reviews in Oncology/Hematology 53,

115-123.

398. Mendoza, F. J., Espino, P. S., Cann, K. L., Bristow, N., McCrea, K., and Los, M. (2005). Anti-tumor

chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome

as targets. Arch.Immunol Ther Exp (Warsz.) 53, 47-60.

399. Okamura, T., Taniguchi, S., Ohkura, T., Yoshida, A., Shimizu, H., Sakai, M., Maeta, H., Fukui, H.,

Ueta, Y., Hisatome, I., and Shigemasa, C. (2003). Abnormally high expression of proteasome

activator-gamma in thyroid neoplasm. J Clin Endocrinol Metab 88, 1374-1383.

400. Kanayama, H., Tanaka, K., Aki, M., Kagawa, S., Miyaji, H., Satoh, M., Okada, F., Sato, S.,

Shimbara, N., and Ichihara, A. (1991). Changes in expressions of proteasome and ubiquitin genes

in human renal cancer cells. Cancer Res 51, 6677-6685.

401. Khal, J., Hine, A. V., Fearon, K. C., Dejong, C. H., and Tisdale, M. J. (2005). Increased expression

of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell

Biol 37, 2196-2206.

402. Smith, H. J., Wyke, S. M., and Tisdale, M. J. (2004). Mechanism of the attenuation of proteolysis-

inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate.

Cancer Res 64, 8731-8735.

403. Hodgkinson, J. L., Peters, C., Kuznetsov, S. A., and Steffen, W. (2005). Three-dimensional

reconstruction of the dynactin complex by single-particle image analysis. Proc Natl Acad Sci U S A

102, 3667-3672.

404. Bhattacharya, N., Wang, Z., Davitt, C., McKenzie, I. F., Xing, P. X., and Magnuson, N. S. (2002).

Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 111, 80-95.

405. Dammermann, A. and Merdes, A. (2002). Assembly of centrosomal proteins and microtubule

organization depends on PCM-1. J Cell Biol 159, 255-266.


153

406. Corvi, R., Berger, N., Balczon, R., and Romeo, G. (2000). RET/PCM-1: a novel fusion gene in

papillary thyroid carcinoma. Oncogene 19, 4236-4242.

407. Sun, Q. Y. and Schatten, H. (2006). Role of NuMA in vertebrate cells: review of an intriguing

multifunctional protein. Front Biosci. 11, 1137-1146.

408. Tong, X., Xie, D., Roth, W., Reed, J., and Koeffler, H. P. (2003). NADE (p75NTR-associated cell

death executor) suppresses cellular growth in vivo. Int J Oncol 22, 1357-1362.

409. Galigniana, M. D., Harrell, J. M., O'Hagen, H. M., Ljungman, M., and Pratt, W. B. (2004). Hsp90-

binding immunophilins link p53 to dynein during p53 transport to the nucleus. J Biol Chem. 279,

22483-22489.

410. Burkhardt, J. K., Echeverri, C. J., Nilsson, T., and Vallee, R. B. (1997). Overexpression of the

dynamitin (p50) subunit of the dynactin complex disrupts dynein-dependent maintenance of

membrane organelle distribution. J Cell Biol 139, 469-484.

411. Kondratova, A. A., Neznanov, N., Kondratov, R. V., and Gudkov, A. V. (2005). Poliovirus Protein 3A

Binds and Inactivates LIS1, Causing Block of Membrane Protein Trafficking and Deregulation of

Cell Division. Cell Cycle 4.

412. Valetti, C., Wetzel, D. M., Schrader, M., Hasbani, M. J., Gill, S. R., Kreis, T. E., and Schroer, T. A.

(1999). Role of dynactin in endocytic traffic: effects of dynamitin overexpression and colocalization

with CLIP-170. Mol Biol Cell 10, 4107-4120.

413. Clark, I. B. and Meyer, D. I. (1999). Overexpression of normal and mutant Arp1alpha (centractin)

differentially affects microtubule organization during mitosis and interphase. J Cell Sci 112 ( Pt 20), 3507-3518.

414. Deininger, M. H., Meyermann, R., and Schluesener, H. J. (2002). The allograft inflammatory factor-1

family of proteins. FEBS Lett. 514, 115-121.

415. Ito, D., Imai, Y., Ohsawa, K., Nakajima, K., Fukuuchi, Y., and Kohsaka, S. (1998). Microglia-specific

localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 57, 1-9.

416. Ito, D., Tanaka, K., Suzuki, S., Dembo, T., and Fukuuchi, Y. (2001). Enhanced expression of Iba1,

ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain.

Stroke 32, 1208-1215.

417. Ohsawa, K., Imai, Y., Kanazawa, H., Sasaki, Y., and Kohsaka, S. (2000). Involvement of Iba1 in

membrane ruffling and phagocytosis of macrophages/microglia. J Cell Sci. 113 ( Pt 17), 3073-3084.

418. Imai, Y. and Kohsaka, S. (2002). Intracellular signaling in M-CSF-induced microglia activation: role

of Iba1. Glia 40, 164-174.

419. Ohsawa, K., Imai, Y., Sasaki, Y., and Kohsaka, S. (2004). Microglia/macrophage-specific protein

Iba1 binds to fimbrin and enhances its actin-bundling activity. J Neurochem. 88, 844-856.

420. Smith, I. F., Boyle, J. P., Vaughan, P. F., Pearson, H. A., and Peers, C. (2001). Effects of chronic

hypoxia on Ca(2+) stores and capacitative Ca(2+) entry in human neuroblastoma (SH-SY5Y) cells.

J.Neurochem. 79, 877-884.

421. Berchner-Pfannschmidt, U., Petrat, F., Doege, K., Trinidad, B., Freitag, P., Metzen, E., de Groot, H.,

and Fandrey, J. (2004). Chelation of Cellular Calcium Modulates Hypoxia-inducible Gene

Expression through Activation of Hypoxia-inducible Factor-1{alpha}. J.Biol.Chem. 279, 44976-

44986.

422. Del Toro, R., Levitsky, K. L., Lopez-Barneo, J., and Chiara, M. D. (2003). Induction of T-type

Calcium Channel Gene Expression by Chronic Hypoxia. J.Biol.Chem. 278, 22316-22324.


154

423. Turcotte, S., Desrosiers, R. R., and Beliveau, R. (2004). Hypoxia upregulates von Hippel-Lindau

tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma. Am J Physiol

Renal Physiol 286, F338-F348.

424. Turcotte, S., Desrosiers, R. R., and Beliveau, R. (2003). HIF-1{alpha} mRNA and protein

upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. J Cell Sci

116, 2247-2260.

425. Hirota, K. and Semenza, G. L. (2001). Rac1 Activity Is Required for the Activation of Hypoxia-

inducible Factor 1. J.Biol.Chem. 276, 21166-21172.

426. Xue, Y., Bi, F., Zhang, X., Pan, Y., Liu, N., Zheng, Y., and Fan, D. (2004). Inhibition of endothelial

cell proliferation by targeting Rac1 GTPase with small interference RNA in tumor cells. Biochem

Biophys.Res Commun. 320, 1309-1315.

427. Udho, E., Tedesco, V. C., Zygmunt, A., and Krucher, N. A. (2002). PNUTS (phosphatase nuclear

targeting subunit) inhibits retinoblastoma-directed PP1 activity. Biochem Biophys.Res Commun.

297, 463-467.

428. Chen, J., Cohn, J. A., and Mandel, L. J. (1995). Dephosphorylation of ezrin as an early event in

renal microvillar breakdown and anoxic injury. Proc Natl Acad Sci U S A 92, 7495-7499.

429. Noda, Y., Horikawa, S., Katayama, Y., and Sasaki, S. (2005). Identification of a multiprotein "motor"

complex binding to water channel aquaporin-2. Biochem Biophys.Res Commun. 330, 1041-1047.

430. Saadoun, S., Papadopoulos, M. C., Hara-Chikuma, M., and Verkman, A. S. (2005). Impairment of

angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 434, 786-792.

431. Saadoun, S., Papadopoulos, M. C., Watanabe, H., Yan, D., Manley, G. T., and Verkman, A. S.

(2005). Involvement of aquaporin-4 in astroglial cell migration and glial scar formation. J Cell Sci

118, 5691-5698.

universitat de barcelonadiposit.ub.edu/dspace/bitstream/2445/36153/8/07.hep_bibliografi… ·...

Documents